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Summary 
 
Using the Swedish Familial Cancer Database, organized and studied by the 
Hemminki group since 1997, the hypotheses that breast, prostate and colorectal 
cancers were affected by familial risks in Sweden (1958-2008) are tested. The null 
hypotheses were rejected for the three cancer types up to the age interval 70-74 yrs 
for which probative data are available.  
Familial risks, represented as age-specific mortality rate ratios, are found to be age 
invariant: 1.9±0.3 (95% CI) for sons or daughters ages 45 to 74 of parents dying of 
colorectal cancer, 2.0 ± 0.2 for sons ages 50 to 74 of fathers dying of prostate cancer. 
The ratio of the risks for daughters of mothers dying of breast cancer ages 35 to 74, 
suggests a different behavior between pre-menopause and post-menopause ages. Can 
be seen as constant at 2.3± 0.3 for all observed age groups. The data could also be 
interpreted as showing a different behavior between the ages before and after 
menopause. The ratio could be decreasing linearly before menopause and be constant 
after menopause  
One potential risk parameter is eliminated as familial because this parameter is 
identical for the general and familial populations: growth rate of preneoplastic lesions.  
Initiation or promotion oncomutation rates in stem cells could account for the familial 
risks in accord with wide variations of mutation rates observed in developing colon 
and lungs. Population parameters such as the fraction of persons in whom initiated 
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stem cells would continue to grow after maturity could also have caused the observed 
familial risks, with oncomutation rates. For familial colorectal cancer, the two 
population parameters considered are of little effect, permitting the conclusion that 
familial colorectal cancer risk lies solely in oncomutation rates.  
Studies of immigrants have demonstrated that fetal/juvenile environmental factors are 
major determinants of organ-specific adult cancer risk. From these considerations 
emerges the hypothesis that the prime determinants of colorectal and other cancer 
risks lie in the fetal/juvenile oncomutation rates. This hypothesis may be tested 
directly by measuring and comparing somatic mutations at defined genetic loci (a.) in 
parents and their adult children (b.) among all adults with and without cancers in a 
specified organ. 
 
Introduction 
In 1896 Roentgen declaimed: “Kampf den Krebs! Krebs ist heilbar.” Because he 
interpreted shrinkage of tumors after x-irradiation as evidence that means could be 
found to cure this dread disease. But in 2009, the American Senator Arlen Specter 
observed: “The lack of progress in cancer therapy in my lifetime has been 
scandalous.”  
Specter’s criticism is supported by the cancer mortality data of the United States 
recorded from 1895-2008 (the data can be viewed at http://mortalityanalysis.mit.edu) 
and similar observations in Asian and European countries in the 20th century. The 
U.S. age-specific adult mortality rates for female breast (Figure1), male prostate 
(Figure 2) and male and female colorectal cancers (Figures 3 and 4) are nearly 
constant. Such improvements as have been made are ascribable to early detection and 
surgery, e.g., cervical and colorectal cancers, or public health efforts as in anti-
cigarette campaigns that decreased lung cancer incidence. There are no explanations 
for other significant decreases such as in the mortality rates for solid tumors of 
juveniles and young adults beginning circa 1940. See female breast cancer, Figure 1. 
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Figure 1: Mortality from breast cancer in all reporting U.S. counties for European American females 
1895-2008. [http://mortalityanalysis.mit.edu]. Data recorded by the U.S. Census Bureau 1895-1935, 
the U.S. Public Health Service, 1936-2008. 
 
Figure 2: Mortality from prostate cancer in all reporting U.S. counties for European American males 
1895-2008. [http://mortalityanalysis.mit.edu]. Data recorded by the U.S. Census Bureau 1895-1935, 
the U.S. Public Health Service, 1936-2008. 
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Figure 3: Mortality from colorectal (lower digestive tract) cancers in all reporting U.S. counties for 
European American males 1895-2008. [http://mortalityanalysis.mit.edu].  
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Figure 4: Mortality from colorectal (lower digestive tract ) cancer in all reporting U.S. counties for 
European American females 1895-2008. [http://mortalityanalysis.mit.edu]. 
Senator Specter might also have aimed his criticism of scientists in the related 
area of cancer causation. In 1971, the oncologist/chemist Charles Heidelberger 
pointed out that “We now know what causes cancer: chemicals, radiation, viruses or 
something else. ” Today other than the risk of lung cancer from cigarette use and skin 
cancer from exposure to sunlight there are no explanations for the causation of the 
most common forms of cancers including colorectal, prostate and breast. For less 
common forms of cancers viral etiology has been demonstrated as in papilloma virus 
and cervical cancer, Epstein-Barr virus and Burkitt’s lymphoma. 
(http://mortalityanalysis.mit.edu). 
Note should be made that Dr. Herrero-Jimenez created the extraordinary 
database for disease mortality records in the United States from which Figures 1-4 are 
copied. The data are provided for many diseases back to 1895 organized in ways that 
permit examination of historical changes at a level unavailable in any other large 
human population. This database has been publically available since 1996 and is 
9 
 
presently found at http://mortalityanalysis.mit.edu.  This thesis would not have been 
possible without his contribution. 
 
 
 
 
Carcinogenesis: 
 The general “two-stage” cascade hypothesis and recent modifications. 
  Cancer has been studied at the population, tissue, cell, genetic and molecular 
levels.  From these studies a coherent model of carcinogenesis expressible as a “two-
stage” cascade of rare events in the stem cell lineage of organogenesis and 
preneoplasia has evolved (NORDLING 1953; PLANT 1955; ARMITAGE & DOLL 
1957; ARMITAGE 1953; Moolgavkar & A G Knudson 1981; A G Knudson 1971; 
Cairns 1975; Herrero-Jimenez et al. 2000). The general picture as of 2008 was that 
inactivation by mutation of about two tumor suppressor genes in a tissue stem cell 
lineage were required to “initiate” some form of “cell at risk,” such as a stem cell. The 
initiated cell continues to grow slowly and to produce more initiated stem cells, thus 
forming a preneoplastic lesion such as an adenomatous polyp of the colon.  One or 
more rare events such as mutations are then believed to “promote” an initiated 
preneoplastic stem cell to become a founder neoplastic stem cell for a neoplastic 
lesion that would grow, usually metastasize, and kill the patient.  
 
This developing model has been adjusted in response to the discovery that 
mutations in adult tissues arose solely in the stem cells of developing tissue: tumor 
initiating mutations appear to be limited to the stem cells of the fetal/juvenile 
period(Sudo et al. 2008)(Kini et al. 2011 as an Appendix).  
Nature of human stem cells. 
In a surprising advance in cancer cell biology, the stem cells of organogenesis, 
preneoplasia and neoplasia have been found to be an entirely unexpected life form, 
the metakaryote, the discussion of which is beyond the scope of this thesis but the 
reality of which must influence all future research (Gostjeva et al. 2006; Gostjeva et 
al. 2009; Sudo et al. 2008; Zheng et al. 2006). In brief, stem cells of organ 
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development in plants and animals are non-eukaryotic cells that use a double stranded 
RNA/DNA genomic replicative intermediate, separate the sister dsRNA/DNA 
genomes without the use of mitosis, then degrade the RNA strand replacing it with a 
DNA strand employing at least two “by-pass” DNA polymerases with high intrinsic 
mutation rates. These cells are highly resistant to killing by x-rays (and radiomimetic 
drugs) and these characteristics explain in large part the failed hopes of Roentgen and 
others who tried to cure cancer by the use of treatments that killed eukaryotic but not 
“metakaryotic” cancer stem cells.  
  
 
Tumor suppressor genes in which required initiating oncomutations occur. 
 Rare familial forms of common cancers killing juvenile or young adults have 
permitted oncogeneticists to identify a few forms of autosomal cancer tumor 
suppressor genes in which mutations required for tumor initiation occur. In these 
cases the afflicted individual inherits one inactivated tumor suppressor allele under 
circumstances wherein the inactivation of both parental copies appears to be sufficient 
for tumor “initiation”: colorectal cancer (APC) (Fearnhead & Wilding 2002), kidney 
cancer (VHL),(Kaelin 2007) nervous system cancers (NFI, NFII) (Brooks 2004), 
retinoblastoma and osteosarcoma (RB)(Yamasaki 2004), basal cell skin carcinoma 
(PTCH)(Leiter & Garbe 2008). To the author’s knowledge, no measurements of 
somatic mutation rates of these genes have yet been reported for the tissues at risk. 
 
No genes are known in which required promoting oncomutations occur. 
 No genes have been found to be the sites of mutations of “promotion”. 
Mutations in the murine/avian oncogenes such as RAS and the gene TP53 were 
originally mistaken for promotional genes because these mutations are frequently 
found in human tumors.  However, mutations in these genes are distributed in sectors 
of human tumors and are not found in all tumor cells of a cancer as would be required 
for a required oncomutation creating a monoclonal tumor. (A hypothesis has been 
advanced that mutations in these genes make the mutant cells responsive to 
hypertrophy by autocrine factors released by tumor cells.) 
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Genes that modulate the rate of mutation in metakaryotic stem cells.  
Other rare familial forms of cancers involve inheritance of inactivated alleles 
in the putative pathways for environmentally induced mutation and thus oncomutation 
of fetal/juvenile stem cells. Examples include the several genes in which inheritance 
of inactivated alleles from both parents results in xeroderma pigmentosum, in which it 
appears that the stem cells of skin epithelium become hypersensitive to mutation by 
sunlight (Cleaver 2000).  
 
Genes that carry mutations that modulate the growth potential of initiated stem cells. 
From the example of cigarette smoking and lung cancer causation comes the 
teaching that a carcinogen need not cause mutations in tumor suppressor genes or 
oncogenes. In fact, a carcinogen may permit/stimulate the growth of pre-existing 
initiated preneoplastic stem cells that do not grow in the absence of the carcinogenic 
agent(Sudo et al. 2008). 
It is possible that persons may be exposed to an environmental agent or inherit a 
mutation that places them at risk of a particular form of cancer relative to 
unexposed/unmutated persons. Such conditions could very well be familial in nature. 
 
Genes that carry mutations that modulate susceptibility to competing forms of mortality that 
share risks with the observed form of cancer.  
Demonstrable sharing of risk between breast cancer and ovarian mortality 
supports the possibility that an environmental exposure or inherited condition could 
alter the degree of shared risk and that persons so affected would have higher or lower 
expectations of death by the observed cancer type relative to the general population. 
Such conditions could also be familial in nature. 
 
Nature of genetic changes that can inactivate tumor suppressor genes or activate putative 
oncogenes. 
Tumor suppressor gene inactivation could occur by point mutations or larger 
chromosomal deletions, rearrangements involving reciprocal or non-reciprocal 
recombination or changes in the epigenetic “punctuation” of the genome. Such 
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changes could be driven by spontaneous processes, exposure to exogenous chemicals 
or radiation or by viruses.  
 The change(s) required for tumor promotion remain unknown. Calculations 
for colorectal cancer risk (Kini et al., 2011, in Appendix) indicate that the requirement 
of a single genetic event would occur at the rate of a typical gene inactivation process, 
such as loss of an active APC colorectal tumor suppressor allele. However, the small 
set of amino acid substitutions that activate known oncogenes would be expected to 
occur at rates approximately 1/100 of gene inactivation rates raising the possibility 
that oncogene activation is not a part of colorectal cancer promotion (Sudo et al. 
2008) . 
 
The continuing search for genes that carry risk for common forms of cancer. 
Modern biology has so far failed to uncover genes that carry risk for common 
cancers, vascular diseases, diabetes and a host of nonlethal conditions. This failure 
may in large part be attributed to the misapplication of the methods of linkage 
disequilibria. These methods have been successfully applied to several thousand rare 
diseases in small families because risk in each family was generally represented by a 
single gene and allele. However for common diseases in which risk would be 
expected to be carried by multiple alleles in any gene and possibly by multiple 
mutations in several different genes the methods of linkage disequilibrium are 
inapplicable (Morgenthaler & Thilly 2007). 
A general approach to studying the genetics of persons with and without 
common cancers was derived to use advanced technology for scanning all known 
human genes to discover which, if any, carried inherited mutations that affected 
cancer risk (Tomita-Mitchell et al. 1998). This same technology, cycling temperature 
denaturing capillary electrophoresis (CDCE) is also applicable to the enumeration of 
point mutations as a function of DNA sequence in human blood samples and organs 
(Ekstrom et al. 2008). These technological advances and demonstrations are cited 
here, as they will be the basis of the suggested future research exploring familial risks 
of cancer.  
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Quantitative cascade models. 
 Despite the many unknowns in cancer development and etiology, the last ~60 
years have seen development of quantitative cascade models. These models describe 
the occurrence of the necessary tumor initiation events (mutations), tumor promotion 
events and their physiological sequelae, growth of preneoplastic lesions and growth of 
lethal neoplasias, respectively (Moolgavkar & A G Knudson 1981; Herrero-Jimenez 
et al. 2000)(Alfred G Knudson 2001)(Meza et al. 2005). In light of recent discoveries 
about stem cells and limitations of initiation mutations to fetal/juvenile stem cells an 
adjusted model of carcinogenesis developed principally at MIT and EPFL groups led 
by Professors W. Thilly and S. Morgenthaler in which Dr. Pablo Herrero-Jimenez and 
later Mr. Lohith Kini  both at MIT should be cited for seminal contributions.(Herrero-
Jimenez et al. 2000)(Kini et al. Appendix I) 
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Figure 5: General idea behind the model of 2-stage carcinogenesis. Stem cells of organogenesis start 
dividing at the beginning of organogenesis and keep on dividing until maturity is reached. After 
maturity, stem cells of organogenesis become adult stem cells that can no longer undergo initiation. 
There are amax divisions from the beginning of organogenesis until maturity of the organ. Stem cells 
that undergo 2 promotion events become preneoplastic stem cells that give rise to preneoplastic lesions. 
These preneoplastic lesions can be initiated both before and after maturity. The initiation of a 
preneoplastic stem cell gives rise to a tumor that ultimately kills the patient.   
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Their general model presently posits “n” required initiating events with rates per organogenic 
stem cell doubling of Ri, and “m” promotion events with rates per preneoplastic stem cell doubling of 
RA. 
Organogenic stem cells are formally modeled as a binomially expanding 
population increasing from 1 to 2amax stem cells at the end of the juvenile period 
(maturity).  
The growth rate per year of preneoplastic stem cells in mature organs is represented 
as the parameter “µ”.  
 
Mortality rate for a particular form of cancer, for the period from maturity to 
extreme old age, at age “t”,  can be described using VOBS(t): the average expected sum 
of lethal events in an individual in any year “t” for t > 16.5 yrs.  
 
VOBS(t) = nRin an!12a
d(1! e!mRAm (g!a)m!12g!a )
d(g! a)a=0
amax
"
    Equation 1             
 
Where “g” is the age of the individual in terms of total stem cell doublings since the 
earliest fetal period, g = a = 0, to the age of individuals observed for cancer death rate, 
where g  = µ (t -19 ) + amax .  
 
In this treatment it is assumed that initiated organogenic stem cells grow after 
maturity as preneoplastic lesions and no other common form of mortality shares the 
same risk factors as the form of cancer being observed. In the case that such 
preneoplastic lesions grow and can undergo promotion in only a fraction of the 
population, that fraction at risk of promotion is designated as “Fprom”.  If there is a 
competing form of mortality sharing the risk factors with the observed cancer, the 
fraction of all deaths among the persons dying from these risk factors in an age 
interval is represented as the constant “f”. Using these population risk factors the 
function VOBS(t) can be transformed into the expected number of lethal events  at age 
“t” given that “Fprom” and/or “f” are less than one.  
 
Equation 2 
! 
OBS(t) = Fprom 1" e
"VOBS (t)( )
Fprom + (1"Fprom )e
"
1
f VOBS (a) da0
t
#
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This form of cancer cascade model is an approximation ignores the probability that 
there may be multiple independent pathways of initiation and/or promotion but does 
provide a platform in which each of the biological variables, initiation mutation rates, 
promotion event rates and preneoplastic growth rates may be considered along with 
population variables in terms of exposure to environmental agents and/or inherited 
conditions of risk. (Details and derivation are in Kini et al., 2011 in preparation, 
APPENDIX I) 
 
Applied to comparison of the age-specific rates of a specified form of cancer, 
the observed age-specific mortality rates of any two defined populations, OBS1 (t) and 
OBS2(t) can be defined over intervals 15-19 through 100-104 as the RISK RATIO1,2 
(t) = OBS1(t) / OBS2(t). In this thesis comparison will be between a “familial” 
population, OBS1 (t), defined as the children of parents who have died of a particular 
form of cancer in Sweden,1958-2008,  and the general population, OBS2(t) comprised 
of all persons born in Sweden, 1933-2008.  
 
Changing cancer risks among immigrant populations 
Population studies distribution of common cancers has been used to try to 
identify the major determinants of cancer risk. In such studies, cancer incidence (i.e 
diagnosis) and/or mortality are compared between different populations. For example, 
comparing the general population and people with an affected siblings (especially 
fraternal and identical twins) or parents (A Altieri & K Hemminki 2007; Goldin et al. 
2005; Kari Hemminki & Czene 2002; Kari Hemminki & Xinjun Li 2004a; 
Lichtenstein et al. 2000; Couto & K Hemminki 2007). 
One of the earliest population studies revealed that daughters of Japanese 
immigrants to the United States born and raised in America had the high breast cancer 
mortality of other North Americans while young Japanese women emigrating to 
America showed the low breast cancer mortality of the native Japanese population in 
Japan (BUELL & DUNN 1965; Thomas & Karagas 1987). The data established a 
basis for believing that some unknown environmental factor was acting in the 
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fetal/juvenile period to define risk for breast, and by analogy, other cancers later in 
life.   
More recently the Hemminki group at DKFZ in Heidelberg has extended these 
observations to the children of Swedish immigrants from countries with different 
patterns of common adult cancers. These studies have found for gastric cancer 
(Mousavi et al. 2011) that the country of fetal/juvenile development defines the adult 
risk. Similar results were shown for other types of cancer as well (K Hemminki 2002) 
(Kari Hemminki et al. 2002). Curiously, the effects appear to be organ specific, a key 
point in thinking about cancer etiology. The mechanism of increased or decreased 
cancer risk in immigrant children as adults has not been defined but as in the case of 
breast cancer in Japanese-American female children a clear case for an undefined 
environmental factor has been made. 
 
These immigrant population studies are equally important for revealing that 
immigration of mature individuals does not change the pattern of age-specific risk 
among cancer sites. These data alone support a conclusion that environmental factors 
that differ among countries do not effect the apparent growth rate of preneoplastic 
lesions, µ, the rate of an event(s), RA,  required for promotion of a preneoplastic to a 
neoplastic stem cell, the fraction of persons in whom preneoplastic lesions of a 
particular kind grow, Fprom, or the degree of competition among causes of death that 
share risks with the observed form of cancer.  
 
 Cancer risks among spouses with long cohabitation in Sweden 
The Hemminki group has also studied the coincidence of cancer rates among 
Swedish couples with at least thirty years of cohabitation and found that there is no 
evidence of shared spousal risk indicating that within Swedish society the adult 
environment does not contribute to risk via the same set of parameters found in adult 
immigrants to Sweden. It appears from these different forms of population studies in 
Sweden that environmental risk factors act only in the fetal/juvenile period. 
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Population studies of common, late-onset cancers reveal both 
environmental and inherited forms of risk 
 
 The idea that certain cancer types run in families was noted in antiquity but 
remains a matter of contention in modern epidemiology. In 1915 after exhaustive 
study of available data for the United States the actuarial epidemiologist Hoffman was 
unable to conclude that familial cancer rates differed from those in the general 
population and concluded: “With regards to heredity and family history, some 
additional observations reemphasize earlier conclusions that the available evidence in 
this respect is in the negative” (Hoffman 1915). On reflection we can now see that at 
that time the numbers of families with two generations living past 65 years of age, 
when cancer rates are highest, was small and that for many major forms of cancer the 
age-specific rates were increasing with each succeeding birth cohort from ~1850 
through 1900. The general impression of familial cancer risks would have been 
derived from those few families of longer-lived individuals dying of the same form of 
cancers and the even fewer families in whom deaths of young adults spanned several 
generations, e.g. familial early-onset cancers.  
Since 1997 the group headed by Professor Kari Hemminki, first at the 
Karolinska Institute and later at the German Center for Cancer Research, has been 
organizing and analyzing the general and familial cancer incidence and mortality data 
available in Sweden since 1958 with the purpose of discovering if a familial risk 
exists for the most common cancers (Kari Hemminki & Bowang Chen 2004c; K 
Hemminki et al. 2007a; Ji & Kari Hemminki 2006; K Hemminki & X Li 2004b; 
Lorenzo Bermejo & Kari Hemminki 2005; Kari Hemminki & Bowang Chen 2005b; 
Kari Hemminki & Xinjun Li 2004c; Kari Hemminki et al. 2007b; Bermejo & Kari 
Hemminki 2005; Kari Hemminki & Bowang Chen 2004b; K Hemminki & B Chen 
2004d; Kari Hemminki & Xinjun Li 2004a; Kari Hemminki & Czene 2002; Kari 
Hemminki & Bowang Chen 2004a; Kari Hemminki & Bowang Chen 2005a; Andrea 
Altieri et al. 2005; Hiripi et al. 2009). When the fraction of persons in the general 
population diagnosed with a cancer in maturity, 30-75 yrs, in the general population 
was compared to that fraction of persons in whom either parent had been diagnosed 
with the identical form of cancer, the ratio (standard incidence rate, SIR.) was found 
to be significantly greater than unity for all cancers. In this case the parents and 
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children were predominately of Swedish genetic heritage and had been raised in a 
relatively homogeneous society. The increased familial risk could thus be attributed to 
inherited traits, environmental factors or combinations of both. Computations of the 
standard incidence rate (SIR) between the population with a familial history of cancer 
and the general population was found to be significantly greater than 1 for all 
common cancers. This means there is an underlying familiar factor which increases 
the risk. Such a factor could be inherited, environmental or a combination of both. It 
is by the kind permission and supervision of Professor Hemminki that the current 
study was made possible.  
 
 
 
Problem of historical changes in age specific cancer mortality 
 A problem arises in comparing cancer mortality rates among persons born at 
different periods of history. Inspection of increases in prostate cancer among 
European American males born 1840-49 to those born 1920-29 shows up to a five-
fold increase among age of death intervals 60-64 through 95-99. A direct comparison 
of fathers’ and sons’ prostate cancer mortality rates for these birth cohorts would be 
performed under a condition in which “fathers” would perforce have lower age-
specific mortality rates than “sons”. Hemminki, based on prostate cancer incidence 
data 1958-2008, reported about a two-fold familial prostate cancer risk. The 
interaction of two phenomena, familial risk and changing historical age-specific risk 
could pose a difficult analytical problem.  
 
 Fortunately, for the cancers examined herein, the age-specific mortality rates 
50-54 through 70-74 years were essentially invariant in the Swedish population 1958-
2008 obviating the problem presented if mortality rates were changing.  
 
Problem of geographical change 
 Cancer rates at specific sites differ between various countries. The existence 
of variations in cancer rates within a country would introduce a bias in the study of 
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familial risk. A familial risk could be due to offspring having a higher chance of 
living in the same region as the one in which their parents grew up.  
 A study by Vatland has shown that there are no variation in cancer rates in the 
United States other than the one expected by chance (Vatland 2001). In this study, the 
author compared the distribution of cancer rates between the communities of the 6 
largest states in the US. The conclusion was that all variations could be explained by 
chance alone and therefore there is no environmental factor affecting cancer rates 
varying between the different communities in the US.  
 A study of such completeness has not been performed in Sweden. Data from 
the family cancer database does not allow such a complete study to be performed. 
However, regional cancer rates and mortality data can be found on the Swedish 
Health and Welfare Statistical Databases. This database is freely accessible online 
(http://192.137.163.40/epcfs/FisFrameSet.asp?FHStart=ja&W=1440&H=900). The 
inspection of the data does not reveal any major variations between the regions for 
each age-group.  Combining the information from Vatland’s work and the Swedish 
database supports the hypothesis that there is no internal variation in cancer rates 
within Sweden.  
DATA: Definitions and treatment. 
Mortality vs. incidence data. 
 
A problem has arisen in recent years as new methods of detecting what are 
believed to be early forms of cancer have been reported as “cancers”.  Both breast and 
prostate cancer diagnoses have been affected by this phenomenon such that the 
number of false positive diagnoses has risen to half or more than half of all diagnoses. 
For this reason the data analyzed in this thesis is restricted to diagnosis at the time of 
death. 
 
This does not mean that the diagnosis at death is accepted here as wholly 
accurate. It means only that of two imperfect forms of data the one with the lesser 
degree of bias has been chosen. The rationale of this choice is presented below using 
Nordcan, a database incorporating the cancer registries of all Nordic countries, 
publicly available at http://www-dep.iarc.fr/NORDCAN/ (Engholm et al. 2010).  
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The data for incidence and mortality of breast cancer (Figures 6 and 7, of prostate 
cancer (Figures 8 and 9) and of colorectal cancer in males (Figures 10 and 11) and 
females (Figures 12 and 13) permit comparison of these two means of expressing the 
population experience of cancer.  
 
Figure 6: Age-specific incidence rates of breast cancer in Sweden for each birth cohort for which at 
least 2 five-year age intervals were available. 
 
Breast cancer incidence (Figure 6) was recorded as rising significantly in birth 
decade cohorts from 1880-89 through 1940-49. The recorded incidence in women 55-
59 years of age rose from ~140 x 10-5 in the 1910-19 cohort to ~280 x 10-5 in the 
1940-49 cohort. In contradistinction, mortality (Figure 7) changes are small or 
undetectable in these same birth decades. The recorded mortality in women 55-59 
years of age was ~60 x 10-5 in the 1910-19 cohort and also ~60 x 10-5 in the 1940-49 
cohort. Reference to the American mortality data [http://mortalityanalysis.mit.edu] 
shows a near constant breast cancer mortality rate for adult women born in the late 
19th through the 20th centuries. The near constant mortality rates suggest small 
progress in treatment of this cancer and the increasing incidence suggests a general 
rise in false positive diagnoses as physicians sought to begin treatments of breast 
cancer with minimum evidence that lesions detected were pre-cancerous or 
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cancerous. It is clear that familial breast cancer risk would better be estimated using 
mortality data.  
 
 
Figure 7: Age-specific mortality rates of breast cancer in Sweden for each birth cohort for which at 
least 2 five-year age intervals were available. 
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Figure 8Age-specific incidence rates of prostate cancer in Sweden for each birth cohort for which at 
least 2 five-year age intervals were available. 
 
 Prostate cancer incidence (Figure 8) was recorded as rising significantly in 
birth decade cohorts from 1880-89 through 1940-49. The recorded incidence in men 
60-64 years of age rose from ~100 x 10-5 in the 1900-09 cohort to ~220 x 10-5 in the 
1930-39 cohort. In contradistinction, mortality (Figure 9) changes are small or 
undetectable in these same birth decades. The recorded incidence in men 60-64 years 
of age was ~40 x 10-5 in the 1900-09 cohort and also ~40 x 10-5 in the 1930-39 cohort. 
Reference to the American mortality data [http://mortalityanalysis.mit.edu] shows a 
near constant prostate cancer mortality rate for adult men born in the 20th century. The 
near constant mortality rates suggest small progress in treatment of this cancer and the 
increasing incidence suggests a general rise in false positive diagnoses as physicians 
sought to begin treatments of prostate cancer with minimum evidence that lesions 
detected were pre-cancerous or cancerous. It seems clear that familial prostate cancer 
risk would better be studied using mortality data.  
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Figure 9: Age-specific mortality rates of prostate cancer in Sweden for each birth cohort for which at 
least 2 five-year age intervals were available.  
 
  
 
 
Figure 10. Age-specific incidence rates of colon cancer in Swedish males for each birth cohort for 
which at least 2 five-year age intervals were available. 
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Colon cancer incidence in males (Figure 10) was recorded as rising 
significantly in birth decade cohorts from 1880-89 through 1930-39 but to a lesser 
degree than recorded for prostate cancer. The recorded incidence in men 60-64 years 
of age rose from ~50 x 10-5 in the 1900-09 cohort to ~70 x 10-5 in the 1930-39 cohort. 
In contradistinction, mortality (Figure 11) changes are small or undetectable in these 
same birth decades up to age intervals 70-74. The recorded incidence in men 60-64 
years of age was ~40 x 10-5 in the 1900-09 cohort and also ~40 x 10-5 in the 1930-39 
cohort. The near constant mortality rates suggest small progress in treatment of this 
cancer and the increasing incidence suggests a general rise in false positive diagnoses 
as physicians sought to begin treatments of prostate cancer with minimum evidence 
that lesions detected were pre-cancerous or cancerous. It seems clear that familial 
male colon cancer risk would better be studied using mortality data.  
 
 
Figure 11. Age-specific mortality rates of colon cancer in Swedish males for each birth cohort for 
which at least 2 five-year age intervals were available. 
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Figure 12. Age-specific incidence rates of colon cancer in Swedish females for each birth cohort for 
which at least 2 five-year age intervals were available. 
 Colon cancer incidence in females (Figure 12) was recorded as rising slightly 
in birth decade cohorts from 1900-09 through 1930-39. This rise is much smaller than 
the one observed for breast cancer. The recorded incidence in women 65-69 years of 
age rose from ~70 x 10-5 in the 1900-09 cohort to ~90 x 10-5 in the 1930-39 cohort. 
Mortality rates (Figure 13) changes are small or undetectable in these same birth 
decades up to age intervals 65-69 but show evidence of decrease in older age-
intervals in successive birth decade cohorts.  The recorded incidence in women 65-69 
years of age was ~40 x 10-5 in the 1900-09 cohort and also ~40 x 10-5 in the 1930-39 
cohort. As was the case for male colon cancer it seems clear that familial female 
colon cancer risk would better be studied using mortality data. That remains true even 
if, unlike breast and prostate cancers, colon cancer mortality data of females contain 
evidence that medical intervention has reduced mortality rates in males and females in 
Sweden in the late 20th century.  
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Figure 13. Age-specific mortality rates of colon cancer in Swedish females for each birth cohort for 
which at least 2 five-year age intervals were available. 
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Figure 14: Incidence and mortality for breast cancer in Sweden from 1960 to 2008 averaged over all 
age intervals.  
 
The basic choice to be made between incidence and mortality is illustrated by 
Figure 14 which shows the incidence and mortality for breast cancer in Sweden, 
1958-2008. It is simply not credible to imagine that a constant rise in cancer incidence 
was matched each year by an offsetting increase in therapeutic efficacy. The use of 
mortality data has, however, the drawback of not taking into account improvements in 
medical practices as has been observed for colon cancer. Recognizing this limitation, 
especially in undercounting the persons actually with a form of cancer because they 
do not die from it, mortality data are used throughout the remainder of this thesis.   
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Source and presentation 
 In 1997 the group led by prof. Hemminki organized the family cancer 
database (FCD) in Sweden.  They linked the administrative family registry of all 
Sweden since 1932 with the Swedish Cancer Registry (K Hemminki et al. 2001).  
The family registry is based on its assignment of identification numbers to all 
residents beginning in 1933. In 1958, the Swedish government instituted a clinical 
record of cancer diagnoses within its health care system and simultaneously registered 
the primary cause of death for each resident. Therefore, the cancer status of every 
individual that died after 1958 is recorded. The group of prof. Hemminki had the 
insight of linking the 2 databases and organizing the data for research purpose. The 
result is the FCD. This is a dataset unique in its kind, for both its completeness and 
size. In Appendix II are provided the raw data for population size and deaths from the 
three forms of cancer treated herein such that the number of deaths recorded 1958-
2008 for each five-year age interval are made available for inspection.  
 
 Within these data, those individuals born 1933-2008 serve as the general 
cohort of children. Each recorded death has been matched to the death records of 
parents to define the familial cohort consisting of the children who died of a specific 
form of cancer with at least one parent who died of the same form of cancer in the 
same 1958-2008 period. Both the general and the familial population are from the 
same generation and contain the same age intervals, from 0-4 through 70-74 yrs.  
 
The total number of deaths recorded for each death age group is as follows: 
 
 
Age 
2Group 
Number of primary deaths by breast 
cancer: general cohort 
Number of primary deaths by breast cancer: 
familial cohort 
2.5 0 0 
7.5 0 0 
12.5 1 1 
17.5 2 0 
22.5 1 0 
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Table 1: Total number of primary deaths by breast cancer in females during each 5 
year interval. The familial cohort is the set of women whose mother died of breast 
cancer.  
 
27.5 6 2 
32.5 13 2 
37.5 49 10 
42.5 132 20 
47.5 347 41 
52.5 571 46 
57.5 842 69 
62.5 759 35 
67.5 539 30 
72.5 252 17 
SUM 3442 258 
Age 
Group 
Number of primary deaths by prostate 
cancer: general cohort 
Number of primary deaths by  
prostate cancer: familial cohort 
2.5 0 0 
7.5 0 0 
12.5 0 0 
17.5 0 0 
22.5 0 0 
27.5 0 0 
32.5 0 0 
37.5 0 0 
42.5 2 0 
47.5 20 3 
52.5 134 13 
57.5 399 37 
62.5 766 65 
67.5 930 71 
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Table 2: Total number of primary deaths by prostate cancer during each 5 year 
interval. The familial cohort is the set of men whose father died of prostate cancer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age 
Group 
Number of 
primary deaths 
by colon cancer 
in males,  
general cohort 
Number of 
primary deaths 
by colon cancer 
in males, 
familial cohort 
Number of 
primary deaths 
by colon cancer 
in females, 
general cohort 
 
 
Number of 
primary deaths 
by colon cancer 
in females, 
familial cohort 
2.5 0 0 0 0 
7.5 0 0 0 0 
12.5 0 0 0 0 
17.5 1 0 0 0 
72.5 625 47 
Total 2876 236 
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22.5 2 0 0 0 
27.5 7 0 3 2 
32.5 3 0 2 0 
37.5 24 0 18 1 
42.5 52 2 38 5 
47.5 95 10 104 7 
52.5 219 14 211 16 
57.5 382 23 379 24 
62.5 538 29 476 19 
67.5 496 30 417 24 
72.5 271 11 221 8 
SUM 2090 119 1869 106 
Table 3: Total number of primary deaths by colon cancer during each 5 years interval. 
The familial population is the set of men or women with at least one parent dead of 
colon cancer. 
 
These mortality rates are defined for each cohort and age-interval as the 
number of persons dying within the interval by the population size within that 
interval. Thus the recorded mortality rate for cohort and age interval in statistical 
parlance is the maximum likelihood estimator (MLE) for cancer risk. It is obvious by 
inspection of Tables 1-3 that  
The low mortality rates early in life prevent meaningful comparisons of 
general and familial cohorts. We have set the minimum number of recorded deaths in 
an interval at 9 before considering the data probative. In Figures 15-18 display all 
non-zero values in the Swedish records. However the calculations used to define 
relative familial to general cohort age-specific risk only considers an age group if nine 
(9) or more deaths are recorded in the age interval in the familial cohort.  
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Figure 15: The MLE of risk for breast cancer for both the familial and general cohorts. The probative 
data points for which there are 9 or more cases are from 35-39 to 70-74 
 
 
Figure 16: The MLE of risk for prostate cancer for both the familial and general cohorts. The probative 
data points for which there are 9 or more cases are from 50-54 to 70-74 
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Figure 17: The MLE of risk for colon in males cancer for both the familial and general cohorts. The 
probative data points for which there are 9 or more cases are from 45-49 to 70-74 
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Figure 18: The MLE of risk for colon in females cancer for both the familial and general cohorts. The 
probative data points for which there are 9 or more cases are from 50-54 to 65-69 
 
 Figure 16Figure 18 show that the familial age- and cancer-specific mortality 
rates are consistently greater than in the general cohorts. In the next section the degree 
of statistical confidence in this conclusion is determined for each cancer and age 
interval for which probative data were available.  It also appears that the ratio of 
familial to general cohort mortality rates are similar over the age-intervals examined. 
This perception is also analyzed blow.   
 
Statistical Methods 
Definition of risk 
The definition of cancer mortality risk in statistical terms is the chances of 
success (death) given a trial (one year of human life). This risk is probability that 
includes 0, 1 and all intervening values. 
 
The risk of dying of cancer is defined as H ! [0,1]   (H stands for hazard. R for risk is 
not used in order not to create confusion with Ri and RA, the mutation rates). 
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As a person either dies or does not die of the cancer studied in any year of 
observation, the probability of the number of deaths among many persons can be 
expressed as a Binomial distribution.  
Binomial distribution: Pk (k|H)= Nk
!
"
#
$
%
&H k (1-H)N-k
 
Where H is the risk, N is the number of trials, k the number of successes (deaths) and 
Pk denotes the probability density function of k.  
 
 It is important to note, that the binomial distribution assumes that the risk 
(probability of a success given one trial) is the same for all trials. If we have the 
number of trials and the number of successes (deaths), it is possible to calculate the 
probability distribution of the risk for a given outcome. 
 
According to Bayes theorem: PH (H|k)=
Pk (k|H)PH (H)
PH (k|H)PH (H)dH!  
This equation has two unknowns. This means that in order to solve it, we need to 
make some hypothesis about PH(H). PH(H) is the a priori distribution of the risk, or 
the distribution of the risk, before any trial is done. A good hypothesis is to assume it 
is uniform between zero and one. As said before, the risk is only defined between 
zero and one, and having no real reason why some risks should be more likely than 
others, it is reasonable to assume it is constant.  
 
Hypothesis: PH(H)=1 ∀ H ∈ [0,1] 
 
Thus :     
PHH (H|k)=
Pk (k|H)
Pk (k|H)dH!
= H
k (1-H)N-k
H k (1-H)N-k dH
0
1
!
 
With this last equation it is now possible to calculate the probability distribution 
(PDF) of the risk, for each set of trials and successes. Although no analytical solution 
will be proposed for the integral in the denominator, it’s numerical calculation is 
trivial.  
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The use of age-specific risk 
Having defined risk, it is now possible to define cancer risk. In that purpose, 
we must first define what is meant by a trial. The chosen definition of a trial is a 
person year. A person year is one person living one year. The number of successes is 
then defined as the number of persons dying of cancer within that person year (as 
explained above mortality will be used instead of incidence). Thus risk is defined as 
the risk of dying of a specific type of cancer during one year. Defined as such, the 
maximum likelihood estimator (MLE) for the cancer risk is: 
 
MLE of cancer risk: 
H= Number_of_casesPerson_years  
 
 It is important to note that the risk for cancer changes during the lifetime 
depending on the age of the individual. The binomial approximation assumes the risk 
to be constant over all trials. Therefore, for the risk has to be defined as age-specific.  
The smaller the age-interval, the greater the validity of the assumption of constant 
risk. However, if the age-intervals are made to be too small, the number of cases 
within each will be to small to be studied. Taking into account this dilemma, 5 year 
age groups are chosen. The risk will be assumed constant over 5 year periods. This 
remains an approximation. However, reducing the width of the age-groups would 
reduce too much the numbers available, and thus increase the variance of the risk 
within an individual age-group.  
 
Testing the Null Hypothesis  
Let Ht and H’t be the general population risk and the familial population risk 
respectively, for each age group t, t ∈ [1 ,2 …n ]. These are defined by Nt, kt, the 
number of person years within each age interval and the number of cancer cases for 
the general population. Respectively, we have N’t and k’t for the familial population.  
  
We now define a parameter ! t = H 't!Ht  
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From probability theory, we have that P! t (! t ) = PH 't (H 't )!P"Ht ("Ht )  (where the 
asterisk means convolution and Pγ is the PDF of the parameter γ).  
 
As for every t: Nt >> N’t and kt >> k’t we can say that the PDF of Ht PHt is narrow 
compared to the PDF of H’(t), PH’(t). This follows from the observation that the 
general population is much larger than the population with a familial risk for a 
specific cancer. 
  
We can therefore assume:P!Ht " !!Ht (where δx is the Dirac function, the neutral 
element of the convolution shifted by x. δx Is an infinitely narrow function with an 
area of 1) 
 
This means we can write P! t (! t ) = PH 't (H 't!Ht )  (Nothing more than the PDF of H’t 
shifted by Ht). 
 
Having the PDF of γ for each age group, allows us to test if the risk is higher at each 
age group. However, we would be interested in knowing if the whole risk is higher in 
general for the familial population. With that goal, we define:  
!T = ! i
i=1
n
!
 
 
Using the same property as before: 
P!T (!T )=P!1*P!2 *...*P!n =PH'1 (H'-H)*PH'2 (H2'-H2 )*...*PH'n (Hn'-Hn ) , this means that the 
PDF of the sum of the risk differences is equal to the convolution of all the PDF of 
the familial risks shifted by the general population risk.  
 
Having a parameter with known PDF which takes into account the differences in all 
the age specific risks, we can formulate the null and alternate hypothesis as follows:  
H0: The cancer risk for the familial population is the same as the one for the general 
population thus γT = 0.  
H1: The cancer risk for the familial population is greater than the risk for the general 
population thus γT > 0. 
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As we can calculate the PDF of γT, we can write: P(!T >0)= P!T (!T )d!T
0
!
! . By 
definition, the P-value =1-P(!T >0)=P(!T<0) .  
 
In the end, for every cancer studied, by looking at the P-value and the PDF of γT, it is 
possible to decide whether or not the evidence is sufficient to reject the null 
hypothesis.  
 
A second way of testing the null hypothesis will also be performed. This test, 
assumes that the number of deaths by cancer in a specific age interval to be a random 
variable following a Poisson distribution. This assumption is in part justified by the 
fact that we have a certain number of events happening in a definite time period. It is 
also assumed that for a high enough number of deaths, the Poisson distribution and 
the Normal distribution are very similar. It is further assumed that the number of 
person years is a constant with no variance in relation to the number of cancer deaths 
for each person year. This seems reasonable since the number of person years is so 
much larger than the number of cancer cases.  
Under these assumptions, we can say that the risk follows a normal distribution with a 
variance equal to the mean. If we further assume that the mean is the observed risk, 
then we can say that: 
k~N(k,√k) and k’~N(k’,√k’) 
Consequently 
H~N(H, kN )  and 
H'~N(H', k'N' )  
At this point we ask what is the distance between R and R’. The distance is expressed 
in quantiles, or standard deviations apart. This process will be done for each age 
group where the number of cases is considered sufficient, that means larger or equal 
to 10 cases. It can be seen that N is far larger than N’. This means that the standard 
deviation of R will be much smaller than the standard deviation of R’ 
For each of these cases we will calculate the distance in quantiles as: 
Q=H'-Hk'
N'  
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The null hypothesis will be considered rejected if all the tested age intervals for a 
single cancer will have a distance between the two risks of three standard deviations.  
   
Calculating the constant ratio between the risks 
From Figure 15Figure 18, it can be observed that the ratio between the 
familial risk and the risk for the general population could be constant. This section 
will show how the ratio, if constant, can be calculated.  
For every age interval, the probability distribution of the familial risk H’ has been 
calculated. R is assumed to be constant relative to H’ and will thus not be considered 
as a random variable. If the ratio is constant: 
For each t: H't=aHt  
 Since Rt is a constant, it is reasonable to say that: 
 For every α: 
P(a=A)= PHt' (AHt )
t
!
  
meaning that the probability of α taking a given value Α is the product over all t, of 
the probabilities of observing H’t=AHt.  
 This calculation gives an estimate of the probability of α taking a certain 
value. The probability distribution of α can be obtained by normalizing the probability 
function: 
  
Pa (a)=
PHt' (aHt )
t
!
P(a=A)dA"
 
 
 The α chosen will be the expectation of α: E(α). 
This method allows for a 3rd test of the null hypothesis. The probability that α ≤ 1 is 
the P-value of the null hypothesis under the assumption that the ratio is constant. 
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Results 
Test of the null hypothsis 
In this study, the null hypothesis has been tested for the following cancers: 
breast, prostate, and colon in males and females. The null hypothesis is tested in two 
different ways.  
 
For every age group, in each of the four cases, an individual P-value has been 
calculated, to know if  γt>0. The result is the following table: 
 
Age group Prostate Breast Colon Male Colon Female 
2.5 6.20E-01 2.63E-01 4.41E-01 3.15E-01 
7.5 6.19E-01 2.62E-01 4.40E-01 3.14E-01 
12.5 6.17E-01 1.97E-02 4.40E-01 3.14E-01 
17.5 6.11E-01 3.63E-01 4.38E-01 3.13E-01 
22.5 6.03E-01 2.58E-01 4.34E-01 3.11E-01 
27.5 5.94E-01 1.55E-02 5.70E-01 1.13E-02 
32.5 5.85E-01 4.81E-02 4.26E-01 3.06E-01 
37.5 5.73E-01 2.25E-05 7.44E-01 1.93E-01 
42.5 5.54E-01 3.39E-07 3.21E-01 4.33E-03 
47.5 4.16E-02 4.73E-10 7.27E-04 3.73E-02 
52.5 4.07E-03 1.00E-06 8.85E-03 1.52E-03 
57.5 7.88E-06 1.53E-10 2.10E-03 1.01E-03 
62.5 1.25E-07 1.69E-02 2.50E-03 9.89E-02 
67.5 1.76E-06 5.73E-04 5.23E-04 6.66E-04 
72.5 2.25E-05 1.44E-04 8.97E-02 2.07E-01 
     
 
Table 4: For each age group, we calculated the P-value of the null hypothesis: γ(t) = 
0. Each P ! value = P! (t ) (! )d!
0
"
# . Every age group represents a five-year interval. For 
example: the age group 37.5 represents the age interval from 35 to 39 years of age.  
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For each distribution, the P-value has been calculated. 
 
 Prostate Breast Colon Male Colon 
Female 
P-value 1.30E-10 0 2.03E-09 1.60E-04 
Total Cases 236 258 119 103 
Table 5: The results from the testing of the null hypothesis. The P-value refer to the 
results from the first type of test. Pval= !TP(!T )d!T
0
!
"  
 
 
These results show that the null hypothesis is rejected for all four cases. In the 
case of breast cancer, the P-value is so low it cannot be calculated within the floating 
comma approximation of MATLAB™.   
We can now show the results of the second test of the null hypothesis. In this test, 
only age intervals that are considered probative are considered, i.e. having at least 
nine (9) deaths recorded in the familial cohorts for any five-year age interval. The 
results show distance in quantiles between the risk of the familial and general 
population.  
 
Age Group Prostate  Breast  Colon 
Males 
Colon 
Females 
37.5   2.53     
42.5  3.30   
47.5   4.31 2.20   
52.5 2.04 3.66 1.88 2.23 
57.5 3.34 4.76 2.29 2.41 
62.5 4.09 1.79 2.27 1.06 
67.5 3.76 2.55 2.58 2.46 
72.5 3.19 2.54 1.01  
Average 3.12 3.18 2.04 2.04 
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Table 6: The results from the second test of the null hypothesis. Each value here 
represents the distance in quantiles between the familial risk and the risk for the 
general population. Only age groups with 9 or more familial cases are here 
considered. The value of each distance  
Q = R '! R
k '
N ' .  
 
 
 
A distance Q =2 means that there is a 95% chance that the 2 values are different.  All 
probative age intervals for prostate cancer have Q values greater than 2. However, 
one age interval for breast cancer and three among male and female colon cancers 
have values of Q < 2.  Therefore according to this test, it is not possible to reject the 
null hypothesis for all probative age groups. This is the reason why the first test was 
performed. It allows for the combination of evidence across all age groups. The 
results of which are presented in Table 5.  
 
Ratio between the risks 
Having rejected the null hypothesis, the ratio between the familial and general 
population can be calculated. For each age groups with probative data, the ratio was 
calculated along with it’s 95% confidence interval. The results are as follows: 
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Figure 19: The ratio between the familial and general population risk for breast cancer as a function of 
age. Showing 2 standard deviation of the ratio (95% confidence interval). The black line indicates the 
calculated value of the ratio if constant, α =2.27. 
 
It would be possible to claim that the ratio remains constant over all ages for 
breast cancer. However, the ratio seems to decrease linearly with age during the first 4 
age groups (35-55 years). The interval showed are 95% CI. Thus, such a result could 
be explained by chance alone and the claim made, that the ratio remains constant 
during the observation period.  
Other interpretations of the evolutions of the ratio between the familial and 
general population risk for breast cancer are also possible.  Figure 19 could be broken 
into 2 separate parts, one relating to women before menopause and the other to 
women after menopause. If the 2 parts are studied separately, the section after 
menopause (approximately over 50) would have a constant ratio of roughly 2, 
whereas the part before menopause would show a downward trend of the ratio.  
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Figure 20: The same as Figure 19. The first 4 age groups seem to indicate a linear decrease in the ratio 
during the period 35-55 years of age. This decrease is illustrated by a hypothetical regression line (the 
green line) for the first 4 age groups. This difference in ratio could be due to early familial breast 
cancer such as BRCA1.  
 
 
Figure 20 shows that the first 4 age groups of breast cancer are aligned on a 
downward slope. The ratios of the first 3 age groups have very large standard 
deviations. As a consequence, the observed downward slope could simply be due to 
chance. However, the possibility that it is driven by some biological phenomenon 
cannot be ruled.  
The decrease in ratio could be due to the small fraction of women that die of 
early familial breast cancer.  Such forms have been identified i.e. BRCA1/BRCA2 
{Dite:2003de}. The high early ratio would be due to a small with a very high risk for 
early breast cancer. As age increases, the risk of the rest of the population increases 
and the fraction of women with a higher risk decreases as they die. The simultaneous 
decrease in the fraction of women at high risk and increased risk of the rest of the 
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population causes the ratio to stabilize between ages 50 and 55. Other explanations 
are also possible.  
 
 
 
Figure 21: The ratio between the familial and general population risk for prostate cancer as a function 
of age. Showing 2 standard deviation of the ratio (95% confidence interval). The black line indicates 
the calculated value of the ratio if constant, α =1.97. 
 
 
46 
 
 
Figure 22: The ratio between the familial and general population risk for colon cancer in males cancer 
as a function of age. Showing 2 standard deviation of the ratio (95% confidence interval). The black 
line indicates the calculated value of the ratio if constant, α =1.85. 
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Figure 23: The ratio between the familial and general population risk for colon cancer in females as a 
function of age. Showing 2 standard deviation of the ratio (95% confidence interval). The black line 
indicates the calculated value of the ratio if constant ,α =1.91. 
 
Figure 21Figure 23 suggest that there is no statistical difference between the ratios of 
any 2 age groups within a cancer. The only exception is the comparison between age 
37.5 and 62.5 for breast cancer. Among over 20 age groups, it is expected by chance 
alone that one would be different when testing with 95% probability. It is therefore 
possible to conclude that the ratios are constant for all age groups for which probative 
data is available.  
  Using the regression method described in the method section, we calculate the 
expected ratio between the familial and general population risk α, in all 4 cases.  
 
 
 
 Prostate Breast Colon Males Colon 
Females 
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Expected slope: α 1.97 
 
2.27 1.85 1.91 
P(α≤1) 1.53E-21 3.14E-33 8.86E-10 4.97E-09 
95% confidence 
Interval 
[1.74 2.23] [2.02 2.57] [1.54 2.19] [1.56 2.23] 
 
 
Figure 24: The familial risk as a function of the general population risk for breast cancer. The 
regression was calculated mentioned in the methods. It is the representation of the ratio between 
familial and general population if assumed constant over all age groups. The value of the calculated 
ratio is α. Since the axis are logarithmic, the value of the slope seen is 1 and is shifted by log(α)  
 
These results can be presented in the form or a plot: familial risk as a function 
of general population risk for all age groups: 
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Figure 25: The familial risk as a function of the general population risk for prostate cancer. The 
regression was calculated mentioned in the methods. It is the representation of the ratio between 
familial and general population if assumed constant over all age groups. The value of the calculated 
ratio is α. Since the axis are logarithmic, the value of the slope seen is 1 and is shifted by log(α)  
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Figure 26: The familial risk as a function of the general population risk for colon cancer in males. The 
regression was calculated mentioned in the methods. It is the representation of the ratio between 
familial and general population if assumed constant over all age groups. The value of the calculated 
ratio is α. Since the axis are logarithmic, the value of the slope seen is 1 and is shifted by log(α)  
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Figure 27: The familial risk as a function of the general population risk for colon cancer in females 
cancer. The regression was calculated mentioned in the methods. It is the representation of the ratio 
between familial and general population if assumed constant over all age groups. The value of the 
calculated ratio is α. Since the axis are logarithmic, the value of the slope seen is 1 and is shifted by 
log(α). 
 
  
For prostate, male colon and female colon cancer, the data indicates a constant 
ratio. The case for breast cancer could be argued both ways. The simplest explanation 
would be that the ratio remains constant over the observed period. Earlier in this 
section is described another possible explanation.  
 Inspection of Figure 21,Figure 22Figure 23 suggests that the ratio remains 
constant over all age groups with probative data for prostate and colon cancer in both 
males and females. There are not 2 age groups that can be said to be significantly 
different at 95% confidence under a pairwise comparison.  
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Biologically based model 
 The model used in this investigation is a two-stage carcinogenesis model 
published in Kini et al. This model uses biological parameters to describe age-specific 
mortality by cancer.  
As postulated by Armitage and Doll (ARMITAGE & DOLL 1957)cancers arise in 
two stages: initiation and promotion. 
 Initiation was defined as the process by which an undefined but numerically 
constant population of cells at risk experienced rare events at a constant annual rate. 
The number of specific oncogenic events required to transform a cell at risk into a 
founder “initiated” cell of a preneoplastic lesion was defined as “n”. Promoted stem 
cells give rise to preneoplastic lesions that continue to divide at the same rate as fetal/ 
juvenile stem cells. This doubling occurs at an annual rate µ, which is kept constant 
even after maturity. The number of promotion events needed (n) is thought to be 2.  
As quoted from Kini et al: 
“Familial heterozygosity for the APC gene is fully penetrant; all heterozygotes 
display multiple adenomas and, if untreated, adenocarcinomas (Kwak & Chung 
2007). This indicates that for most colorectal tumors the number of required initiating 
mutations “n” ≥ 2.  
 
Values of the geometrical mean of initiation mutations assuming values of n other 
than 2 are thus clearly discordant with APC and OAT colonic mutation rate estimates. 
These facts, derived from clinical genetic observations in both inherited and sporadic 
forms of colorectal cancers are wholly consistent with the conclusion that n = 2 and 
inconsistent with values of n ≠ 2.” 
 
The number of specific oncogenic events required to transform a cell at risk 
into a founder “promoted ” cell of a neoplastic lesion was defined as “m”. Kini et al. 
shows that best fits are obtained with m=1 when n=2.  
Kini et al. (2011) have incorporated in a model for colorectal cancer the 
findings that promotion has to happen in the fetal/juvenile period. This model 
stipulates that the promotion of a stem cell give rise to a preneoplastic lesion that 
grows with the fetal/juvenile organ up to maturity. It then continues to increase at a 
growth rate close to that of juvenile tissues (Herrero-Jimenez et al., 2000). In each 
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growing preneoplastic colony a cell can undergo promotion at any point after 
initiation.  Only people that have become promoted during the fetal/juvenile period 
can undergo initiation.  
The resulting incorporating these findings to calculate age-specific mortality 
(OBS) is: 
OBS(g)=
Fprom 1-e
-2ln(2)Ri2RA 2g ae-RA 2
g-a
a=0
amax
!"
#
$
$$
%
&
'
''
Fprom+(1-Fprom )e
-1f 2ln(2)Ri
2RA 2k
k=0
g
! ae-RA 2
g-a
a=0
amax
! Equation 3 
 
 
In this equation, time is expressed in g, the number of stem cell doubling. If we wish 
to convert the time in years, we apply the following relation: 
 
t= g-amax
µ
+19  thus: g=µt+amax -19      Equation 4 
 
The parameters meaning is as follows: 
 Ri: is the rate of an initiation mutation for every stem cell division 
 RA: is the rate of the promotion mutation for every stem cell division 
 Fprom: The fraction of the population in which an initiated stem cell will grow to form 
a preneoplastic lesion.  
 f: “Represent the fraction of persons that die of the observed cause among the set of 
mortal diseases with shared risks and synchronous changes in death rates” (Quoted 
from Kini et al 2011, in appendix).  
 amax: the number of stem cell divisions in an organ when an individual reaches 
maturity.  
 µ: The division rate of stem cells in an individual’s preneoplastic lesion. 
The model can also be presented in the same form as is done in the introduction.  
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 OBS(g)= Fprom 1-e
-VOBS (g)( )
Fprom+(1-F)e
-1f VOBS (a)da0
g
!
 Equation 2 
 with:  
 
! 
VOBS(g) = 2ln(2)Ri2RA2g ae"RA 2
g"a
a= 0
amax
# Equation 1  
N.B. The value and meaning of VOBS has already been discussed in the introduction. 
 
The model assumes that the number of promotional events happening at age g follows 
a Poisson distribution. As a consequence, the probability of observing no events at  
age g is: e!VOBS (g) . Thus the probability of observing at least one event is: 
 P(at least one event at age g) = 1-e-VOBS (g) .  
 As Fprom is the fraction of people in which a neoplastic lesion grows, the upper 
term represents the probability of having a promotional event in the general 
population of people alive at age g.   
  If the whole population is at risk, i.e Fprom=1, the lower term =1. 
Therefore:  
 OBS(g)=1-e
-VOBS (g)
 
 In the case Fprom ≠1, the population at risk is dying faster than the general 
population. This would need to be accounted for. The fraction of people alive is the 
fraction of people at risk, minus the fraction of people that died of the modeled 
disease and related concurrent causes.  
 The assumption that the number of lethal events in an interval [0,g] follows a 
Poisson distribution is made. It follows from the previous assumption, where the 
number of lethal events happening during an interval [g-1,g], is Poisson distributed. 
From the definition of VOBS(g): 
 VOBS(a)
0
a
! da = The expected number of lethal events happening in an 
individual up to age g. 
 Using the same argument as the upper term,  
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 e
-1f VOBS (a)da0
g
!
=The probability of not having died of the studied disease or any 
concurrent form of death up to age g.  
  
 The probability of being alive at time g is: 
 Fprom+e
-1f VOBS (a)da0
g
!
-Fprome
-1f VOBS (a)da0
g
!
=The fraction of people at risk + The fraction 
of the people that did not die – Those that have died of the studied disease or any 
concurrent form of death.  
 This equation can be factorized to: Fprom+(1-Fprom )e
-1f VOBS (a)da0
g
!
, the lower term 
of the general equation.  
   
Cancer is though to arise through a variety of possible pathways. The 
observed mortality is the sum of the mortality caused by the all the different 
pathways. These distinct routes leading to cancer could each produce a different age-
specific mortality curve in the population where they occur. However, not knowing 
the nature of these individual pathways, the only possibility is to consider the average 
mortality for the general population. It follows that this observed mortality is the 
average mortality for the different groups of the population in which cancer occurs 
through a different pathway.  
 
Having defined the general equation, we will now formalize the ratio between 
mortality for two populations: the familial population and the general population. 
Without loss of generality, we can write 2 separate equations, one for the age specific 
risk in the general population and one for age specific risk in the familial population. 
The only difference will be the values the parameters can take. 
For the general population we have: 
 
! 
OBS0(g) =
F0 1" e
"2ln(2)Ri02RA0 2g ae"RA0 2
g"a
a=0
amax0
#$ 
% 
& 
& 
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) 
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"
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f0
2ln(2)R i02RA0 2k
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g
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g"a
a=0
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#
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and for the familial population: 
 
! 
OBS1(g) =
F1 1" e
"2ln(2)Ri12RA1 2g ae"RA1 2
g"a
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amax1
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The ratio between the age specific risk for the general population and familial 
population is thought to remain constant over the ages. The ratio can be expressed as: 
 
! 
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This remains constant for each 5 years age interval between 30 and 74 years of age, as 
shown by analysis of the data.  
 
If F0 equals1, it follows that F1 also equals 1. In this situation, the equation simplifies 
to: 
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! 
OBS1(t)
OBS0(t)
=
1" e
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a=0
amax1
#
1" e
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a=0
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#  
In all individuals that are heterozygous for the APC gene, APC -/- polyps appear to 
grow (Alfred G Knudson 2001; Kwak & Chung 2007). Therefore F=1. The similarity 
between the colon and prostate age-specific mortality curve suggest that the 
assumption should be maintained. For a more complete description of the assumption 
that F=1, please refer the reader to Kini et al.  
The equation is highly non-linear. Therefore, no attempt to analyze the parameters 
analytically will be made.  
 
Application of model to data to discover parameters that 
may be affected by familial risk. (limitation to case of n=2, 
m=1) 
 
 The first set is to calculate values of the parameters that accurately fit the 
mortality data of prostate cancer and colon cancer in males. Only male cancers will be 
analyzed in this section.  
 The fitting process will give an estimate of the values the parameters could 
take in the general mortality by a specific form of cancer. The different parameters 
will be modified one by one until a curve that portrays an increase similar to the one 
observed in the familial population is observed. This process will give an estimate of 
the variation of each parameter needed to explain the observed increase.  
 Note that the values in the model are population averages. People vary in size, 
and therefore the size of the organs varies as well. The mutation rate can also vary 
from person to person by a range of nearly 10-fold (Sudo et al. 2008). The values 
used in the model are therefore averages of a heterogeneous population. A difference 
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in the value of a parameter between the familial and general population, therefore 
reflects a change in the distribution.  
 The effects of the variables in the models are not independent of each other. 
For example, for a large amax , a variation in RA will have more impact than if amax is 
small.   
 
Preneoplastic growth rate: µ  and fraction of deaths among persons at risk 
from cancer at observed site: f 
 
The effect of a variation in f or µ is shown in Figure 28 and Figure 29, for prostate 
and colon cancer respectively.  
 
Figure 28: The effect of variations in µ (mu) and f on the age specific mortality by prostate cancer. We 
can clearly see that a variation in f or µ would not keep the ratio between the original curve and the 
varied cure in the observed age-range. 
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Figure 29: The effect of variations in µ (mu) and f on the age specific mortality by male colon cancer. 
We can clearly see that a variation in f or µ would not keep the ratio between the original curve and the 
varied cure in the observed age-range. 
 The graphs show that a variation in µ or f would result in a change in the 
observed slope of the curve. This results in the ratio changing during the observation 
period. Consequently the conclusion that difference between the familial population 
and the general population is a difference in amax, Ri, RA, Fprom or a combination of 
these factors can be reached. However, due to the complexity of the problem they will 
be analyzed separately.  
 
 Study of familial APC concluded that everyone is at risk for colon cancer. Thus F is 
assumed equal to 1. This assumption is extended to prostate cancer based on the 
similarities of the mortality curves.  
Figure 30 and Figure 31 show the curves resulting from the variation of amax, 
Ri, and RA independently for prostate and colon cancer. The reference curve is the one 
that best fits the mortality for the general population. The variations of the parameters 
are aimed to fit the mortality of the familial population.  
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Figure 30: The effect of the variation of amax, Ri and RA, on the age specific mortality for prostate 
cancer. The reference is the curve calculated with the parameters supposed to fit the general population 
mortality. To obtain the other 3 curves, we have varied the corresponding parameter while keeping the 
other constant until it was close enough to the mortality of the familial population. In order to fit the 
familial population, Ri is multiplied by 2, RA is multiplied by 1.7 and 1 is added to amax. 
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Figure 31: The effect of the variation of amax, Ri and RA, on the age specific mortality for colon cancer 
in males. The reference is the curve calculated with the parameters supposed to fit the general 
population mortality. To obtain the other 3 curves, we have varied the corresponding parameter while 
keeping the other constant until it was close enough to the mortality of the familial population. In order 
to fit the familial population, Ri is multiplied by 2, RA is multiplied by 1.5 and 1 is added to amax. 
Number of stem cell doubling until maturity (related to organ size): amax  
amax represents the number of stem cell doubling in the organ studied. For the 
case of the colon, the number of stem cells is thought to be equal to the number of 
crypts since each crypt has a stem cell at the bottom.  
The graphs show that for both colon and prostate, amax would need to increase by 1 in 
order to fit the risk of the familial population. An increase of 1 means a doubling of 
the number of stem cells in the organ and therefore a doubling of the size of the 
organ.  
A doubling in the number of stem cells of the colon corresponds to a doubling 
in the length. For amax to explain familial risk, the familial population must have a 
colon twice as long as the general population. This increase in colon length must be 
shared between parents and children. A link between the length of the colon in 
parents and the length of the colon in children is very plausible. However, it is not 
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plausible that the population whose parents died of colon cancer have a colon twice as 
large as the general population.  
Based on the results of the model, the conclusion that a variation in colon size 
could not alone explain the familial risk for cancer is reached.  
Similar arguments can be made for prostate cancer. In both cases, a doubling of the 
organ is needed to double the risk of cancer.  
 
Rate of initiation mutations: Ri 
 Figure 30 and Figure 31 show that Ri is 1.8 and 2 times larger in the familial 
population for prostate and colon cancer respectively. The difference between 1.8 and 
2 can be considered as not significant. Therefore the variation needed for Ri to explain 
familial risk is roughly 2-fold.  
 These numbers reflect an average of the population under study. The 
population is known to be heterogeneous for mutation rates (Sudo et al.). This 
heterogeneity is due to inheritable factors, environmental factors or both.  
 According to the model, the average Ri among the people that died of cancer 
is higher. For Ri to be the underlying factor of familial risk, the combination of shared 
environment and inheritable factors must account for a doubling in Ri among the 
offspring.  
 Since the distribution of mutation rates in the population is unknown, no 
attempt will be made to calculate the correlation between parent Ri and offspring Ri.  
 These findings suggest Ri is possibly the underlying factor behind familial 
risk. 
Rate of promotion mutation: RA 
Figure 30 and Figure 31 show that RA needs to be 1.5 times larger for the 
prostate and 1.4 times larger for the colon cancer to describe familial risk. This 
difference can be considered as small.  
It is not known if Ri and RA are different. It is well possible that RA=Ri. In 
which case they would vary together. This, however, would not change the problem. 
In this case, Ri=RA would 1.7 times higher in the familial population as in the general 
population.  
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 These findings suggest RA is possibly the underlying factor behind familial 
risk. 
 
Fraction at risk of promotion given initiation : Fprom 
 The fraction of the people at risk is believed to be equal to 1. A change in 
Fprom would decrease the mortality rate. This change in age-specific mortality has a 
constant ratio to the original curve in the ages between 20 and 75.  
The mortality of the general population was fitted under the assumption that Fprom=1. 
Any change in Fprom will therefore reduce the calculated mortality. As a result, no 
attempt will be made to fit the familial population when changing the value of Fprom. 
Figure 32 Figure 33 show the prostate and colon cancer curves and the modified 
curve with Fprom =0.5.  
 
Figure 32: The effects of varying Fprom on the age specific mortality by prostate cancer. Age specific 
mortality was calculated using the same parameters as in Figure 30. The other curve was calculated 
using again the same parameter but by using an Fprom=0.5. Since we believe that Fprom=1, the curve 
calculated using Fprom=0.5 does not fit the familial population and is even smaller than the general 
population mortality. This graph is informative as it tells us how a variation of Fprom will impact age-
specific mortality.  
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Figure 33: The effects of varying Fprom on the age specific mortality by colon cancer. Age specific 
mortality was calculated using the same parameters as in Figure 31. The other curve was calculated 
using again the same parameter but by using an Fprom=0.5. Since we believe that Fprom=1, the curve 
calculated using Fprom=0.5 does not fit the familial population and is even smaller than the general 
population mortality. This graph is informative as it tells us how a variation of Fprom will impact age-
specific mortality 
 This means that if Fprom is different from 1 and is the underlying cause of 
familial risk, it would need to be smaller than 0.5 in the general population. This 
follows from the fact that Fprom is a fraction and is therefore always smaller or equal 
to 1.  
 If Fprom is to explain familial risk it would have to be very small in the general 
population (ie. Much smaller that 0.5). Otherwise, the link between a parent being at 
risk and an offspring being at risk would be too strong.  
For example, if Fprom =0.5: If a parent dies of cancer he is necessarily at risk. Since 
Fprom1=2*Fprom0 it follows that Fprom1=1. This means that if a parent is at risk, the 
offspring are necessarily at risk as well. A small value of Fprom is not compatible with 
the observed mortality rates by prostate and colon cancer in the general population. 
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Furthermore, it would contradict the observations made in the study of APC mutated 
families.  
 These results therefore suggest that the fraction of people at risk is not the 
underlying factor of a familial risk for cancer.  
  
Discussion  
 
Strengths and limitations of the statistical tests 
 The difference between risks is tested. Risk is assumed constant within every 
interval studied. No correction is applied to account for the resolution (i.e. the 
approximation that mortality remains constant in 5 years intervals). However risk is 
changing within every studied interval. In some cases it doubles between the 
beginning and the end of the 5 years interval. Taking smaller intervals would have 
reduced the numbers too much. These findings need to be taken into account when 
interpreting the result of the test.   
 Difference in risk was calculated for every age group. The final test verifies 
whether the sum of all differences is greater than zero. What does this mean when the 
risk is changing by four orders of magnitude during lifetime? It means that the 
difference in risks is also changing by a similar order of magnitude. Consequently, the 
later, and larger risks, will contribute much more to the final sum than the earlier, and 
smaller, ones. On one hand, this is a problem. However, the later, and larger risks, 
have much larger numbers that the earlier ones. As a consequence, the way the total 
difference in risk is tested, gives more importance to the age groups with larger 
numbers because they are the ones with larger risks. Some age groups can have no 
cases, as happens for all the age groups before 40 years of age in prostate cancer. The 
difference in risk is thus centered around zero for those ages. The number of person 
years in those early groups are very high. Consequently, the distribution will be 
extremely narrow and approach a Dirac function, the neutral element of the 
convolution. These age groups will therefore only contribute in a minor way to the 
final PDF of γT, and thus to the test result. Even so, the early age groups, if they are 
the same and with a risk equal to zero, will still contribute by slightly broadening of 
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the final distribution of γT. It is impossible to know if this is the optimal way of doing 
or not. The only thing is to keep these facts in mind when interpreting the results.  
 
 The second test uses a simpler approach. It assumes that the number of cases 
follows a Poisson distribution in all age groups. It also assumes that the Poisson 
distribution is approximated by a normal distribution with a variance equal to its 
mean. These assumptions are only valid if there are sufficient numbers of familial 
cases in an age group. The limit is set to 9 cases, a number that is reasonably large to 
make the second hypothesis valid. This test can therefore only test some of the data 
points. It is also to be noted that it provides no way of combining evidence. This 
means that the test result needs to be interpreted for each age group individually. This 
visualization allows a better understanding of the significance of each age group. In 
fact, from the first method it is hard to judge if there are a small amount of age groups 
dominating the general effect.  
 The impossibility of testing the null hypothesis globally raises some questions. 
For example, we can only test four age groups in the case of female colon cancer. Of 
these four age groups, three have a distance in quantiles between the means, Q, 
greater than 2 and around 2.5. However, one of them is around 1. What can be 
concluded? With a distance Q of 1 it is impossible to reject the null hypothesis. A 
distance of 2.5 is enough to reject it. In the example of colon cancer in females, the 
null hypothesis is rejected in 3 out of 4 age groups. Using this method alone, it is 
impossible to draw a conclusion as to whether or not we should reject the global null 
hypothesis that the overall familial risk is greater than the general population risk. 
However, supported with the 1st method, it offers strong evidence to refute the null 
hypothesis. 
  
Calculating constant ratio 
 
Figure 21Figure 23, indicate that within each case, the ratio does not vary 
significantly between the age groups. There is today no method to measure absolute 
evidence in favor or against a linear regression. Therefore the claim that the ratio is 
constant can only come from the pairwise comparison between the risk ratios of each 
age group within a cancer. Once it is observed that there is no statistical difference 
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between the ratios, the total ratio over all age groups was calculated using a form of 
linear regression. This method provides a way of estimating the constant ratio 
between the familial and general population risk for cancer. It also provides another 
test of the null hypothesis. It is to be noted, that the parameter P(α < 1) tests the null 
hypothesis under a very specific assumption: That the ratio between the two risks is 
constant for all age groups. It is a test that alone would not be sufficient, since one 
could always contradict the hypothesis that the ratio is constant, even when it looks 
constant. However, it is a further support for the previous tests done.  
 
Identified parameters 
 The results indicate that if a parameter is to be the source of a familial risk for 
cancer, it is most likely to be mutation rates. The model used considers a situation 
where initiation and promotion can have different rates.  Modeling using only one 
mutation rate for both initiation and promotion is also possible.  
 To support the conclusion is the fact that mutation rate is know to vary at least 
7-fold in the lung, and 6-fold in the colon. This means that only a weak link in 
mutation rates between parents and offspring would cause an increase in cancer risk 
in the offspring in parents that died of cancer.  
 Since the distribution of mutation rates is unknown in the general population, 
the correlation between mutation rate in parents and offspring is impossible with the 
current data.  
 The model used is valid within the assumptions described in Kini et al. It is a 
way in which one can interrogate the influence of various biological parameters on 
the age-specific mortality by cancer. Therefore the drawing of conclusions needs to 
be very careful. Consequently, the conclusions that have been drawn from it are valid 
as long as it is assumed that cancer is the result of dividing cells undergoing random 
mutations that can lead to the disease.  
 For a complete discussion of the model used, please refer to Kini et al. 
(attached as an appendix).  
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Future studies 
 The results presented here clearly establish the existence of a familial risk. 
Thus, the offspring of affected parents are at higher risk for cancer than the general 
population, for all age groups. It is also shown that the ratio between the risks of the 
familial population to the general population is roughly 2. This value seems to be true 
for all studied cases. Using a model for carcinogenesis, it can be shown that a change 
in the size of the organ, the fraction of people at risk or an increase in promotion or 
initiation mutation rates, would increase the age-specific risk by a constant factor for 
all the observed age groups. Any combination of these changes would also keep the 
ratio constant. From the analysis of the changes, it can be concluded that the mutation 
rates are the most likely factors to explain a large portion of the familial risk. A future 
study in the area of familial risk for cancer, should focus on measuring mutation rates 
in the general population and establishing its distribution. Such a study must also 
investigate the link between the mutation rates in the parents and offspring. 
Furthermore, this study should establish the distribution of mutation rates among 
cancer patients. Last, the study should measure the mutation rate distribution in the 
offspring of parents that died of cancer. If this distribution turns out to be different, it 
will be possible to determine how large is the contribution of familial mutation rates 
to the familial risk of cancer. This measurement would also help validate the model 
for carcinogenesis used in this project.  
  
 The study described in Sudo et al.(Sudo et al. 2008) describes a method that 
can be used to measure mutation rates in human organs. Unfortunately it is an 
extremely tedious method requiring large amount of organ tissue. Furthermore, there 
is no reason for which one should believe that mutation rates are the same throughout 
the human body. As a consequence, the study would have to be performed for every 
organ of interest. Thus a different method would have to be developed to study 
mutation rates in people.  
  
 In Sudo et al, biopsies of different sizes were excised from human lungs. 
These biopsies were then analyzed using constant denaturing gel electrophoresis for 
known genes (CDGE).  CDGE is a method that allows for the quantification of 
mutant DNA strands in a DNA pool. CDGE allows the quantitative measurement of 
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DNA mutations in a large DNA pool with resolution up to one mutant copy in 104 
normal copies [reference]. Furthermore, using large thermo-cyclers, it has a 
throughput of 96 DNA pools per hour. The use of CDGE to calculate mutation rates 
in an organ is described in Sudo et al. Biopsies were taken at various positions in a 
lung. From each biopsy, DNA was extracted, and amplified. CDGE was used to 
quantify the mutant fraction in those pools for various gene fractions. With the mutant 
fraction and the biopsy size, the size of the mutant colony size was calculated. 
Knowing the size of the colony gives information about which time in the 
fetal/juvenile development the mutation occurred. Form there, the authors calculated 
the mutation rates.  
 A similar method to the one used by Sudo et al. could be used for calculating 
mutation rates in any organ. However, this would require many biopsies being taken 
from various organs in the same persons, and then repeating the experiment for many 
people. This would be far too cumbersome to do on a large scale. Furthermore, it 
would not be possible on live people. This calls for another method of obtaining DNA 
from organs. One such possibility is the isolation of macrophages from the blood. 
Macrophages phagocytize dead cells from all organs. Thus, a macrophage could be 
treated in a similar way as a biopsy was in Sudo et al. Running a CDGE analysis on a 
macrophage containing DNA from a specific organ, would give the mutant fraction in 
the region the macrophage was located previous to being in the blood circulation.  
 The challenges involved will be discussed individually and can be stated as 
follows: 
 
1. Efficiently isolating the macrophages from a blood test: 
Macrophages represent about 1 in 105 cells in circulation in the blood. Since there are 
about 5 106 cells/µl in blood, there are about 5 104 macrophages/ml of blood.  
 
 
2. Defining which organ the DNA in the macrophage came from. 
 To calculate organ-specific mutation rates, the macrophages need to be sorted 
according to the organ of provenience. This could be achieved through the 
identification of organ specific mRNA or proteins identified and measured by specific 
a fluorescent antibodies. Since the macrophages phagocytized cells in the organ, it 
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still contains some mRNA original from the dead cell. The use of fluorescent probes 
followed by fluorescent activated cell sorting (FACS) sorting should separate the 
macrophages. It is still unclear whether this method will provide the accuracy and 
throughput required.  
 
3. Estimating the size of the mutant colony from the fraction of mutated DNA in 
the macrophage:  
CDGE allows the quantification of mutant fractions. However, what is needed to 
measure the mutation rate is the size of various mutated colonies. A link must be 
established between the mutant fraction in the DNA inside a macrophage and the size 
of the mutant colony on the site from where the macrophage comes.  
4. Defining for which genes will be used to calculate the mutation rates:  
CDGE can only be used for one DNA fragment at a time. Furthermore, the use of 
CDGE requires the a priori knowledge the sequence that is being analyzed. Therefore, 
the set of gene fragments that will be analyzed will have to be determined a priori. 
Mutation rates for different DNA locus can be different [reference missing]. Thus the 
gene fragments could introduce a source of bias in the measurement.   
 
5. Increasing the throughput of CDGE: 
Using a standard 96 well thermo-cycler, it is possible to analyze 96 DNA pools in 1 
hour. Each pool can contain up to 104 different DNA strands for a single mutant to be 
detected. If one needs to analyze 100 sectors per organ, 5 organs, 100 gene fragments 
per person, the number of pools to analyze would become 50 000 per person. This 
amounts to roughly 500 hours of CDGE per person. It is yet unclear how many people 
the study should involve. However, it is clear the throughput of CDGE will have to be 
increased. The easiest way could simply be to increase the number of capillaries in 
one thermo-cycler.  
 
The study would be possible provided solutions are found to the here-above stated 
challenges.  
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Conclusion 
The difference in risk between the familial and general population is found to 
be significant for prostate, breast and colon cancer. Three methods were used to reject 
the null hypothesis. The first used the definition of risk as the parameter of a binomial 
distribution and calculated the probability distribution of the risk using an assumption 
on the a priori distribution of the risk. The second method assumed the number of 
cases to be Poisson distributed and as a consequence so is the risk. The third method 
is an extension of the first method . The calculated probability distribution of the risk 
is used to calculate the ratio between the familial and general population risk. The 
probability that the ratio is greater than 1 is a test of the null hypothesis under the 
assumption that the ratio remains constant throughout the age groups. Of these three 
methods, the first and second are independent. Thus the null hypothesis is tested and 
rejected by at least 2 independent means.  
The ratio between the familial and the general population risk is calculated. 
The calculated ratio is observed to remain constant. The behaviors or the ratio 
between the risks of breast cancer for the earlier age groups could indicate a change in 
the ration in the ages before menopause. Even so, the evidence is not sufficient to 
reject the possibility that the ratio remains constant for breast cancer as well.  
The data shows that pairwise comparison between the ratios taken for various 
age groups within a cancer cannot establish that they are significantly different. Thus 
a method of regression is used to calculate the ratio across all age groups. This total 
ratio is found to be approximately 2. No significant difference was found between the 
values of the ratios of prostate and colon cancer. There is one pairwise comparison in 
breast cancer that would indicate a significant difference. It is not possible to 
conclude that this difference is not due to chance alone. Thus the general conclusion 
is that the ratio between familial cancer risk and general population risk remains 
constant over all observed ages.  
The observation of constant ratio is not compatible with a difference in preneoplastic 
growth rate between he familial and general population (µ). It is not compatible either 
with a variation in the fraction of people dying of diseases with shared risk (f) 
between both populations.  
Mathematical modeling using the 2-stage model shows that to explain familial 
risk, the number of stem cells in the average organ should double between the familial 
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and general population. These findings restricted the explanation of familial risk to 
the fraction of people at risk and the mutation rates.  
Studies of rare early onset familial colon cancers (due to a mutation in the 
APC gene) suggest that the fraction of people at risk is 1 for colon cancer. Therefore 
leaving mutation rates as the only explanatory factor for familial cancer risk.  
Finally, a method to measure mutation rates in the general population is 
outlined. Carrying out the described experiment would measure the distribution of 
mutation rates in a population. The comparison of the mutation rates distribution in 
the familial and general population would confirm or reject hypothesis here proposed 
and give insights into the process of carcinogenesis.  
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Appendix 
Data for mortality of the general and familial population 
Follows the raw data of mortality that were used in the analysis of familial risk. For each cancer will be presented the number of deaths 
for the familial and general population within each year for each age. Both the familial and general population number represents the number of 
deaths in the offspring population (i.e. the offspring of recorded parents). 
On the horizontal axis are the calendar years and on the vertical axis the age of death.  
Female Breast cancer, general population: 
	   1964	   1976	   1978	   1979	   1980	   1981	   1982	   1983	   1984	   1985	   1986	   1987	   1988	   1989	   1990	   1991	   1992	   1993	   1994	   1995	   1996	   1997	   1998	   1999	   2000	   2001	   2002	   2003	   2004	   2005	   2006	   2007	   2008	  
13	    1                                
15	      1                              
17	           1                         
21	       1                             
28	               1       1             1 
29	               1        1        1     
30	                          1          
31	                       2             
32	   1      1                     1      
33	                  1  2                
34	                 1   1   1 1            
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35	                  1     2 1 1 1          
36	                  1 1        1 2  1 1     
37	                   1 2 2   1 2  1   2      
38	         1 2                1          
39	             1   1 1 1 3 2   3  2 1 1 1  1 1 2    
40	                  1 1 1   1 1  1     2 1    
41	          1     1  2 1 4  1 5 3  3 2 1  1 1  1    
42	         1       3   4 5 1 1 1 2 3  1 2   1  1   
43	          1    1   1 2 4 4 1 4 2   3 3 1 2 1   1 2 1 
44	               1   3 5 5 4 2 2 2 3 1 3 1 3     1  
45	       1 1 2         4 6 6 9 2 4 2  1 1 1 1 3  1   3 
46	     1       1     1 4 4 10 4 2 2 1 2 2 3 1 3 4  1  2 1 
47	        1     1 1 1  2 5 11 1 9 8 7 5 5 5 5 5 2 5 2 2 3 1 1 
48	           1 1      5 7 11 4 2 4 2 6 5 3 2  2 1 1 4 1  
49	         1   1  1  2 2 6 10 8 6 10 11 6 3 9 7 2 3 3 5 3  1  
50	                  6 13 9 6 6 7 9 4 6 5 3 6 5 2 1 3   
51	               1  1 8 8 7 10 10 11 5 4 9 3 6 4 5 2 5 2 1 1 
52	                  5 12 6 4 11 18 12 7 6 6 8 6 5 5 2 1 2 3 
53	               1   7 8 13 8 9 7 10 7 4 7 6 3 8 5 5  1 2 
54	                1  7 13 17 10 3 6 15 13 14 10 8 7 5 5 5 3 4 1 
55	                  4 11 10 9 8 11 6 15 15 9 12 16 3 5 10 7 1 5 
56	                  4 11 9 9 6 15 8 6 12 20 12 6 9 10 10 6 6 4 
57	                  6 12 11 8 10 6 9 11 11 11 14 8 6 12 9 6 4 4 
58	                  5 12 17 9 4 11 13 9 10 15 9 14 13 14 7 7 6 7 
59	                  1 7 8 12 15 11 12 10 15 9 16 15 10 10 8 8 9 6 
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60	                   9 7 6 17 14 13 10 11 11 9 10 5 15 9 13 13 15 
61	                    3 2 11 8 12 10 9 12 13 10 9 10 14 8 10 12 
62	                     3 4 10 13 16 7 15 7 6 14 11 17 22 11 5 
63	                      1 12 7 11 6 11 10 8 7 11 12 11 8 9 
64	                       2 9 5 5 20 6 13 17 12 9 17 8 11 
65	                        3 9 6 7 9 14 6 11 10 14 13 16 
66	                          10 2 13 11 12 18 14 12 14 10 
67	                          2 6 7 5 16 11 16 10 21 16 
68	                           1 8 11 21 12 9 14 10 15 
69	                            2 12 6 20 13 10 14 17 
70	                             3 10 12 13 17 8 18 
71	                              2 9 10 14 13 6 
72	                               4 8 21 13 13 
73	                                4 13 10 7 
74	                                 5 6 13 
75	                                  6 8 
76	                                   5 
 
Female breast cancer, familial poulation 
	   1976	   1983	   1987	   1990	   1991	   1992	   1993	   1994	   1995	   1996	   1997	   1998	   1999	   2000	   2001	   2002	   2003	   2004	   2005	   2006	   2007	   2008	  
13	   1                      
28	                        1 
29	            1             
32	                   1      
34	         1                
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35	            1             
36	                 1  1      
37	             1 1     1      
39	                 1   1 2    
40	         1                
41	           1 1  2  1     1    
42	        1 2     1           
43	    1 1  1    1    1          
44	        1 1      1   1       
45	       1   2               
46	      1 2 1   1  1   1 1        
47	        1  1 1 1 1 1 1  1 1 1  1 1 1  
48	         1    1   1 1    1    
49	         2  1 1   2 1   1 4     
50	          1  1  1  1   1   1   
51	        3 2  1   1 1    1    1  
52	           1 1 1       2 1 1   
53	        2  1  1 1  1   1  1 1   1 
54	        2 1    2 1 1 1 2     2  1 
55	        1 1 2    2 3 2 1 3  1     
56	         2   2   1 1 2    1  1  
57	           1 1  1   3 3  2 2 1 2 1 
58	         2 2 1   1 1 3  1 1 2  1  1 
59	         1  1  1 1    2 1 1   2  
60	            1 1   2  2  1 1  1 1 
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61	           2 1  1    1   1  1  
62	           1      1 2 1  1  3  
63	              1  2     1   2 
64	               1    1     1 
65	                 1   2  1   
66	               1  2   2 2 1 1 1 
67	                1  1  1 1  2 2 
68	                  2 1    1  
69	                   1  2 1   
70	                     1 1  1 
71	                    1 1 2 2  
72	                      3  2 
73	                       1 1 
74	                        1 
75	                       1  
 
 
Male prostate cancer, general population 
	   1988	   1990	   1991	   1992	   1993	   1994	   1995	   1996	   1997	   1998	   1999	   2000	   2001	   2002	   2003	   2004	   2005	   2006	   2007	   2008	  
41	       1    1      1 1     
43	                    1   
44	     1                  
45	       1 2   1            
46	    1                   
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47	       1         2 1      
48	       3     1     1   1   
49	       1  2 1   1 1 2 2 2      
50	   1    1  3 2 6 2 2 3  1       
51	     4 1 4 3 2 2 2 2 3 2  2 2 1 1  1 1 
52	     1 3 1 2 2 2  1 2 2 2  3  1  4  
53	    1 1 4 7  1 3 3 4 1 3  2 1  6 2 3 1 
54	     2 2 3 2 2 3 7 4 3 3 1 2 1 4  2 2 4 
55	    1 1 1 4 4 3 4 3 2 4 2 3 7 2 6 5  2 1 
56	    2 1 6 5 4 4 3 2 3 5 5 3 3 8 4 2 4 5 7 
57	     2 2 5 4 4 3 2 5 8 3 7 7 10 8 7 4 5 2 
58	     3 3 6 3 4 3 7 3 5 3 10 13 6 7 7 5 8 4 
59	      1 4 6 4 7 7 7 13 7 6 10 9 5 13 7 12 8 
60	       5 7 3 10 14 9 10 7 6 13 13 13 9 13 10 13 
61	       2 8 8 9 7 7 11 7 13 11 21 11 16 16 12 9 
62	         7 7 8 7 9 17 13 10 16 15 11 8 14 12 
63	         2 8 11 12 9 20 12 11 12 7 12 18 15 23 
64	          3 8 16 11 15 18 13 12 19 14 28 22 14 
65	           1 6 11 13 20 14 23 20 21 14 15 20 
66	            2 7 21 20 18 25 21 26 15 10 26 
67	             2 10 19 23 17 22 24 21 22 21 
68	              2 15 13 20 32 34 21 24 23 
69	               8 16 18 33 33 32 32 26 
70	                3 11 22 17 20 33 32 
71	                 10 18 27 31 26 26 
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72	                  12 31 26 35 43 
73	                   12 17 33 29 
74	                    10 26 36 
75	                     12 27 
76	                      13 
 
Male prostate cancer, familial population 
	   1990	   1991	   1992	   1993	   1994	   1995	   1996	   1997	   1998	   1999	   2000	   2001	   2002	   2003	   2004	   2005	   2006	   2007	   2008	  
41	      1                
43	                   1   
45	       1               
48	      1                
49	            1  1        
50	          2            
51	    1  1 1 1    1   1       
52	       1      1     1    
53	     1     1 1 1          
54	       1 1 1 1          1 1 
55	   1   1 2  1     1  1    1  
56	     1   1    1 1 1  3    2  
57	     1 1       1 2 1 2 1  1   
58	          1    1    1   1 
59	       1    1 1    2  2  1  
60	      1 1 1 1 1 1 1 2  1 2  3 3 1 2 
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61	        1 1  1  2 1 1 2 1 2  1 1 
62	        1 2 1   2  1 3  1 1 2 2 
63	           1 1 1 2 1 2  1 1 1 4 
64	         1    3  1 1 3 3 3 1  
65	            1 1 1 2 5  1 1 1 3 
66	              2 1 2  4 4  3 
67	            1   1  2 1 3   
68	              2 4 2 1 3 3 3 3 
69	                2 3 3 3 2 1 
70	                2  1 2 3  
71	                2 3 3 2 6 1 
72	                  3 1 1 3 
73	                    2 5 
74	                    1 5 
75	                     1 
76	                     1 
 
Male colon cancer, general population 
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Male colon cancer, familial population 
	   1989	   1990	   1992	   1993	   1994	   1995	   1996	   1997	   1998	   1999	   2000	   2001	   2002	   2003	   2004	   2005	   2006	   2007	   2008	  
40	      1                
42	               1       
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45	   1 1                  
46	       1    1           
48	      1   1      1       
49	        1    1  1        
50	                   1   
51	            1  1        
52	     1         1        
53	     2  1      1         
54	       1   1 1 2          
55	     1           1      
56	               1    1   
57	      1    1  1   1   1 1  1 
58	             1     1  1  
59	        2 1 1  1 1  1   1  1  
60	            1  1      1  
61	          1     1   1    
62	        1  1  1  1   2  3 1 3 
63	           2  1    1    1 
64	              1 1  1 1  1  
65	           1  1  2 1 1  1 2  
66	              1 1   1  1 1 
67	                 3  2   
68	                3 1 1   3 
69	                1 1    1 
70	                  1  2  
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71	                 1   1  
72	                 1     
73	                  1 1 1  
74	                   1  1 
76	                     1 
 
Female colon cancer, general population 
	   1964	   1974	   1976	   1977	   1978	   1979	   1980	   1981	   1982	   1983	   1984	   1985	   1986	   1987	   1988	   1989	   1990	   1991	   1992	   1993	   1994	   1995	   1996	   1997	   1998	   1999	   2000	   2001	   2002	   2003	   2004	   2005	   2006	   2007	   2008	  
26	            1                          
28	           1                           
29	   1                                   
31	                                     1 
32	                    1                  
35	     1                                 
36	    1             2                1     
37	    1   1             1    1 1             
38	            1    1       1 1              
39	            1  1          1 1             
40	      1      1         1 1   1    1    1     
41	        2                  1  1          
42	                  1  1  1 1 1 1 1 2    1 1      
43	         1           1 1       1 1 1        
44	          1          1 2  2     1    2 1     
45	                    1 1 2 1 1 1 2  2 3   1  1    
89 
 
46	               3   1  3 4  1  2 1  3 1  1   1 2 1  
47	           1    1   1    1 3 1   1 1       1   
48	                1  1  3 2  2 4 1 2 1 1 2    2 1   1 
49	               1  2 2 1 1 4 1 2 3 3   2 1 3  1 2     
50	              1    1  1 4 7 1 1 4 1 2 1 1  1   1 1 3 1 
51	             1       3 4 2 5 4 5 6 1 3 2 2 1 1 1   1  
52	                    3 2 2 2 2 2 4 4  5 2  1 4   1 1 
53	                  1   4 1  4 5 3 7 3  4 3 2 1 1 2 1  
54	                 1  1 3 6 3 2 6 5 3 6 2 1 5 4 2 1 1 5 1 2 
55	                    2 4 9 5 3 6 2 5 4 4 6 9 2 2  2 1 3 
56	                   2 3 8 7 1 9 6 3 6 2 4 2 4 3 6 6 3 3 2 
57	                    2 4 6 5 5 6 4 6 3 7 6 3 2 4 7 3 1 7 
58	                    1 1 5 2 3 4 4 5 4 5 3 7 4 4 3 7 7 5 
59	                     1 2  3 7 4 6 7 5 5 4 7 9 3 2 7 3 
60	                     1 4 6 6 8 14 3 3 4 6 5 6 4 8 5 5 7 
61	                      1 1 5 5 5 4 9 7 5 11 6 2 8 5 4 5 
62	                       1 5 5 7 9 8 14 6 7 11 11 7 6 10 5 
63	                        1 2 12 6 5 6 7 5 11 7 6 13 10 9 
64	                         1 3 6 6 6 8 12 10 7 3 8 8 8 
65	                          2 6 6 9 10 5 8 8 7 8 12 12 
66	                           1 4 8 9 8 10 6 11 9 7 10 
67	                            2 6 11 8 6 6 9 10 12 13 
68	                             2 6 6 7 10 10 12 10 8 
69	                              2 7 11 10 15 11 17 14 
70	                               3 6 6 9 16 17 19 
90 
 
71	                                4 10 9 8 8 12 
72	                                 2 7 7 13 13 
73	                                  2 3 16 11 
74	                                   4 7 9 
75	                                    2 11 
76	                                     2 
 
Female colon cancer, familial population 
	   1964	   1982	   1989	   1991	   1992	   1993	   1994	   1995	   1996	   1997	   1998	   1999	   2000	   2001	   2002	   2003	   2004	   2005	   2006	   2007	   2008	  
28	    1                    
29	   1                     
36	                   1     
40	       1                 
41	            1            
42	         1 1              
44	              1          
45	            1            
47	         1    1           
48	       1                 
49	           2    1         
50	       1             1    
51	           1 2    1        
52	        1       1         
53	     1   1            1    
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54	          1 1  1   1 1       
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          1 2     2 1      1 
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                  1    2  
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      1 1     1   1 2 1   1  1  
58	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65	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67	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68	                1 1  2     
69	                 1 1 1 1 1   
70	                  1      
71	                   1  1   
72	                   1 1    
73	                     1 1 1 
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ABSTRACT 
Age-specific colorectal cancer rates increase sub-exponentially from maturity, reach a 
maximum, then decline in old age. The “two-stage” model of Armitage and Doll 
related adult cancer rates to exponential growth rates of preneoplastic colonies and the 
number and rates of mutations necessary to begin preneoplasia (initiation) and then 
neoplasia (promotion). Initiation mutations were assumed to occur throughout adult 
life in a population homogeneous for risks but the model did not account for the 
maximum, then declining rates observed. This discordance has been ascribed to 
diagnostic errors in old age, stratification of population risks and/or limitation of 
initiation mutations to the fetal/juvenile period. Now, however, nuclear and 
mitochondrial mutations in adult lungs have been found distributed as Luria-Delbruck 
expansions that indicate restriction of initiation mutations to stem cells of the 
fetal/juvenile period, specifically to newly-discovered mutator/hypermutable 
metakaryotic stem cells. A computer program, CancerFit v5.0, has been developed to 
test the fetal/juvenile initiation hypothesis. Best fits with lifetime incidence data are 
obtained with (a.) APC gene mutation rates derived from observations in FAPC 
patients, (b.) two, and only two, initiation events and (c.) preneoplastic stem cell 
doubling rates approximating that of juvenile growth. Concordance is further 
improved by population risk stratification consistent with variation in adenoma 
numbers observed among FAPC patients. Public health implications: conditions 
affecting stem cell fetal/juvenile oncomutation rates should potentiate adult cancer 
rates. They may account for shifts of organ-specific cancer rates among immigrants 
and exponentially decreasing untreatable pediatric tumor rates during the past seventy 
years. 
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INTRODUCTION 
The rates of most forms of cancer decline from the first year of life to a minimum in 
mid- juvenile years, increase sub-exponentially into old age then decline in extreme 
old age [1, 2]. Armitage and Doll [3] sought to reconcile the increasing rate of cancers 
with adult age in terms of new understandings of genetics and genetic change of the 
1950s. They posited that any single cell at risk in a static adult cell population could 
be “initiated” by “n” required genetic events. An initiated cell founded an 
exponentially growing preneoplastic colony in which any cell at risk was “promoted” 
to a tumor-founding cell by “m” independent events. Their original “two-stage” 
model of initiation and promotion assumed that initiation mutations occurred 
throughout life in adult tissues only and that the population was homogeneous with 
regard to oncomutation and preneoplastic growth rates. Their model did not predict 
the observed maximum cancer rate of old age. (A brief history of quantitative cancer 
models is offered in Supporting Information.) 
More than fifty years after their pioneering postulates, the number, nature and origins 
of oncomutations that initiate the slow growth of preneoplastic lesions and later 
promote a preneoplastic cell to the rapid growth of neoplastic lesions remain obscure 
for most common cancers, e.g. lung, breast, prostate, pancreas. Clinical observations 
have shown that preneoplastic lesions of several organs continue to grow after 
maturity and give rise to lethal neoplasias through extreme old age. Promotional 
genetic changes, if any, must therefore occur throughout life in preneoplastic 
colonies. But genetic or epigenetic events have not yet been found that fulfill the 
logical requirements for a rare human promotion mutation: each tumor cell of the 
tumor and its derived metastases must carry the rare promoting genetic/epigenetic 
event(s). 
However, for a few common cancer types, e.g. colorectal, kidney, nervous system, 
and skin, autosomal tumor suppressor genes have been identified both copies of 
which must be genetically inactivated for initiation to occur [1]. We chose one of 
these, colorectal cancer, for this study. 
Familial heterozygosity for the APC gene is fully penetrant; all heterozygotes display 
multiple adenomas and, if untreated, adenocarcinomas [2]. This indicates that for 
most colorectal tumors the number of required initiating mutations “n” ≥ 2. The fact 
that colorectal preneoplastic or neoplastic colonies can grow in all persons in which 
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they arise indicates that the population is not stratified relative to growth of 
preneoplastic or neoplastic colonies. But the range of hundreds to thousands of 
adenomas observed in colons among individuals inheriting an inactivated APC allele 
suggests population stratification with regard to APC somatic initiation rates [1, 2].  
 
Based on evidence drawn from epidemiology, clinical histopathology and somatic 
genetics we and others have postulated that colorectal cancer initiating mutations in 
the APC gene occur only in the fetal/juvenile period [4, 5, 6] specifically in a 
mutator/hypermutable metakaryotic stem cell lineage [7, 8, 9, 10] and that the 
majority of point mutations inactivating this gene are attributable to copying errors of 
DNA polymerase β on undamaged DNA [11]. Here we provide (a.) newly organized 
data on mortality from lower gastrointestinal tract cancer, (b.) a model of 
carcinogenesis in which initiation is limited to the fetal juvenile period, (c.) a suitable 
computer program and (d.) tests of the concordance of predictions of the model with 
observed cancer rates.  
Mortality Data Base: historical age-specific cancer rates. 
U.S. cancer mortality numbers and populations recorded 1900-2006 by the U.S. 
Census Bureau (1900-1935) and the U.S. Public Health Service (1936-2006) have 
been matched and organized with regard to gender, ethnicity, calendar interval of 
birth, “h”, (ten years: 1800-09, 1810-19, …), calendar year interval of death, “y” (five 
years, 1900-04, 1905-09,…), and age at death interval, “t” (five years, 0-4, ….100-
104)) [11, http://mortalityanalysis.mit.edu]  (Supporting Information Table S1). These 
data allow computation of raw age-specific lifetime mortality rates, OBS(h,t), as the 
number of deaths by the observed cause divided by the number of persons alive at the 
beginning of the one-year interval “t”. Thus OBS(h,t) is an approximation of the 
conditional probability that a person would have died of the observed cause given that 
he or she was still alive. However, cancer models predict incidence rates, INC(h,t), as 
a calculated approximation, CAL(h,t), of conditional rates of deaths absent covariant 
factors such as competing forms of death or the effect of medical intervention in the 
age/time interval observed. Transforming observed raw mortality rates, OBS(h,t), to 
estimates of incidence rates, INC(h,t), requires correction for several sources of bias. 
In extreme old age (t = 100-104) death rates approach ~0.3 per year and must have 
reduced the number of deaths by the observed cause. Correction for this bias consists 
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of determining the total raw mortality rate for each five year age interval, TOT(h, t), 
and defining the coincidence-corrected mortality rate at the third or middle year, 
OBS*(h,t) as OBS(h,t) /[1-TOT(h,t) + OBS(h,t)]. Accounting for historically 
improving five-year survival rates, SUR(h,t), is also required for some cancers such 
as colorectal cancers [12, 13, 14]. The expected incidence rate, INC(h, t), adjusted for 
these considerations is: 
 
INC(h,t ) = OBS(h,t)/( [1-SUR(h,t)][1-TOT(h,t) + OBS(h,t)] ).  Equation 1 
 
Diagnostic errors at death may also be expected and these would vary among cancer 
types, age at death, historical year of reporting etc. so that INC(h,t) as defined here is 
an approximation and its uncertainties must be considered in comparing predictions 
of models, CAL(h,t), to incidence represented by INC(h,t).  
Lower gastrointestinal tract cancer mortality in the U.S., 1900-2006. 
Deaths from cancer of the lower gastrointestinal tract (present ICD9 codes: 152, 153, 
154) are predominantly deaths from colorectal cancer 
[http://mortalityanalysis.mit.edu]. Figure 1a uses a semi-log plot to illustrate the 
transformations from raw mortality rates to incidence rates: from OBS(h=1890-99,t) 
to OBS*(h=1890-99,t), then to INC(h=1890-99, t). Also shown is the result of the 
same transforms of the succeeding decade, INC(h= 1900-09,t), which yielded similar 
estimates of for all values of “t”. (Supporting Information Table S2) 
In Figure 1b the OBS*(h,t) vs. “t” is presented on a semi-log scale for each of 
successive birth cohort intervals, “h”, from 1800-09 through 2000-06. These data 
demonstrate that colorectal cancer death rates in older adults (t > 65) rose throughout 
the birth cohorts of the 19th century reaching an approximately stable maximum in 
and after the birth cohort of 1880-89. In Figure 1c these same data are plotted so that 
changes OBS*(h,y) as a function of age of death interval, “t” may be seen as 
functions of historical year of death interval “y”. This form of presentation shows a 
significant decrease in older adult death rates ascribable in whole or part to advances 
in medical practice after 1950 that increasingly effect each successive birth cohort 
(Supporting Information Table S2, Figure 1) [http://mortalityanalysis.mit.edu, 12, 13]. 
In Figure 1d the data are plotted as OBS*(y, t) vs. “y” to illustrate the historical 
changes within each age of death interval, “t” as a function of historical year of death 
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interval, “y”. This form of presentation reveals that colorectal cancer mortality rates 
in children and young adults have decreased exponentially from ~ 1940 through 2006.  
Algebraic elements of the two-stage model.   
Limitation of initiation mutations to the fetal/juvenile stem cell doublings. 
Growth of normal fetal/juvenile stem cells is here modeled as a series of “a” net 
binomial doublings (a = 0, 1, 2, …, amax) in which “n” required initiation mutations, i, 
j, …n, occur in any order at constant mutation rates Ri, Rj, …,Rn per doubling [13, 
14]. The number of newly initiated stem cells in doubling period “a” is n (∏n Ri) a(n-1) 
2a. In the fetal/juvenile model organogenic stem cells are posited to reach maturity 
represented by “amax” doublings with high constant mutation rates and to undergo 
metamorphosis to maintenance stem cells with no net additional net cell growth and 
much lower mutation rates [9]. 
Assuming each of the ~107 adult colonic crypts to be represented at juvenile/adult 
metamorphosis by a single metakaryotic stem cell, the number of net doublings at 
maturity, amax, is about 23.25, i.e., 107~ 223.25 [13,14]. The metakaryotic 
mutator/hypermutable stem cell lineage of human organ anlagen appears to begin in 
gestational week 4-5 with creation of two metakaryotic stem cells from symmetrical 
amitosis of a single precursor embryonic mitotic stem cell at a = 0 [10]. At birth, a 
colon contains ~220 colonic crypts each containing a basal metakaryotic stem cell 
[10]; thus at birth, a ~ 20, at maturity, a = amax ~ 23.25.  
Promotion mutations during preneoplastic stem cell doublings. 
After initiation in any fetal/juvenile doubling “a” growth of preneoplastic stem cells 
as a colony is modeled as a series of “g - a” binomial doublings (g-a = 0, 1, 2, …) in 
which “m” required promotion mutations (A, B, …m, occur at constant mutation 
rates RA, RB, …,Rm per doubling) [13,14]. The expected number of newly initiated 
stem cells in preneoplastic doubling period “g-a” is m (∏m RA) (g-a)(m-1) 2(g-a). Under 
these assumptions the number of organogenic doublings “a” at initiation and the 
number of preneoplastic doublings “g-a” after initiation sum to “g” which is a very 
useful continuous variable because it describes the age of humans in terms of 
continuous stem cell doublings through fetal/juvenile and then preneoplastic growth. 
In each organogenic doubling interval “a” new preneoplastic colonies are created 
(initiated) and these colonies grow until promotion and subsequent death remove 
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them. The extinction of preneoplastic colonies at “a” and at “g - a” is driven by the 
supra-exponential term exp[-m (∏m RA (g-a)(m-1) 2(g-a)]). 
If all persons have the same numbers and rates of “n” required initiation and “m” 
required promotion oncomutations and all initiated cells grow at the same average 
rate as preneoplastic stem cells (homogeneous risk) the expected number of 
promotional events at the binomial doubling age interval “g”, V(g) may be 
represented as: 
 
V(g) = n (∏n Ri) ∫(a=0, a=amax) a(n-1) 2a d(1-exp[-m ∏m RA (g-a)(m-1) 2(g-a)]) /d(g-a)  da 
 
 ≈ n (∏n Ri)∑(a=0, a=amax) a(n-1) 2a d(1-exp[-m (∏m RA (g-a)(m-1) 2(g-a)]) /d(g-a)  
Equation 2          
 
This process is illustrated in Figure 2 in which the contribution to promotion at age 
“g” from initiation at each organogenic doubling “a” is shown to rise and fall with “g-
a”. The sum of these terms from initiations in all organogenic doubling intervals “a” 
approximates well the observed lifetime incidence rate of many cancer types 
including colorectal cancer: it increases sub-exponentially, reaches a maximum in old 
age and declines appreciably in extreme old age. The earliest initiations of fetal 
organogenesis drive the tumor incidence rate of juveniles and young adults, the 
initiations of adolescent organogenesis drive the tumor incidence rate in extreme old 
age. 
In addition to homogeneous risk it is here assumed pro tempore that there are no synchronously 
competing forms of death with shared risks for colorectal cancer and that all events of initiation 
and promotion are randomly assorted among persons as in a Poisson distribution. Under these 
conditions the expected number of newly promoted lesions through the end of any doubling 
interval “g”, CAL(g), is:  
 
CAL(g) = (1-e-V(g)) Equation 3 
 
Age of death, “t”, and doubling age of promotion, “g”. 
Cancer mortality data corrected for coincident deaths within the year of death, 
OBS*(h,t) and its derived estimate of incidence, INC(h,t) are calculated in five year 
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age-of-death intervals 5-9 ,…., 100-104 years such that deaths in any age interval are 
plotted at the mid interval , i.e. deaths within the interval 50-54 are plotted at 52.5 
years. CAL(h, g) is, however, approximated as the instantaneous rate of promotion at 
the end of each stem cell doubling interval “g”.  
To account for the difference between adult age at promotion and death we adopt 
Armitage and Doll’s [3] estimate of 2.5 yr, which is in accord with estimates of net 
tumor growth rates that would produce a gross untreated tumor mass in excess of 
three kilograms [12, 13]. Death at age t = 72.5 is thus attributed to promotion at age t 
= 70. 
The relationship between human age at death in years, “t”, and stem cell doubling age 
at promotion, “g” is then defined if there is a constant average adult preneoplastic 
stem cell annual doubling rate, “µ”. Given the age of maturity for males as 16.5 yr 
[13, 14] at g = amax and an average interval of 2.5 yrs between promotion and death 
absent medical intervention:        
 
g = µ (t -16.5 – 2.5 ) + amax = µ (t -19 ) + amax       Equation 5 
 
Stratification of risks in the population. 
We have previously represented the fraction of the population in whom all of the 
potential conditions necessary for cancer death are present as “F” imagining that a 
person either is or is not at risk for a necessary oncogenic process. The corresponding 
fraction in which one or more necessary condition is absent has been represented as 
(1-F) [12, 13, 14]. Stratification need not, however, be an “all or none” phenomenon. 
Children’s grow to different sizes, which may create stratification with regard to the 
maximum number of stem cells at risk of initiation 2a max. Children grow at different 
rates and so may the preneoplastic lesions in different persons. Stratification with 
regard to mutation rates in fetal/juvenile expansion has been noted for both 
mitochondrial and nuclear genes [9]. In progress is an effort to incorporate 
stratification with regard to initiation and promotion oncomutation rates and the 
growth rates of preneoplasias. The use of “F” in this present report serves as first 
approximation in stratification accounting insofar as it values of (1-F) > 0 could 
represent in part a fraction of persons that are not initiated greater than expected by a 
Poisson distribution of initiations among all persons with a single set of initiating 
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mutation rates. Equation 4 rewritten to account for stratification in this way creates 
the model:  
 
CAL(g) = F(1-e-V(g))/ [F + (1-F) e ∫ V( γ) dγ] evaluated from γ = 0 to g.  Equation 6. 
 
Competing synchronous forms of mortality. 
Epidemiological observations have also demonstrated that forms of cancer may share 
environmental or inherited risk factors with another, e.g. breast and ovarian cancers, 
in which the death rates increase synchronously with age 
[http://mortalityanalysis.mit.edu]. The term ”f” has been introduced to represent the 
fraction of persons that die of the observed cause among the set of mortal diseases 
with shared risks and synchronous changes in death rates [12, 13, 14]. Equation 6 
rewritten to account for both stratification and a hypothetical synchronous competing 
form of mortality with shared risk factors with the observed disease in this way 
creates the model:  
 
CAL(g) = F(1-e-V(g))/ [F + (1-F) e ∫ 1/f V(γ) dγ] evaluated from γ = 0 to g.  Equation 7. 
 
RESULTS 
Application of the model to age-specific colorectal cancer incidence in a specific 
cohort. To test the null hypothesis that the function CAL(h,t) calculated from 
stipulated parameters did not differ significantly from the observed age-specific 
incidence function INC(h,t), a means was required to assess the variation expected by 
chance among independent trials. As an approximation of this variation we compared 
age-specific incidence rates of lower G.I. tract cancer observed for European-
American males born 1890-99 to the rates for those born 1880-89 and 1900-1909 
(Figure 1a) as shown in Supporting Information Table 2. This comparison comprises 
any real changes in colorectal cancer incidence during the twenty year historical 
interval (expected to be negligible by inspection of Figure 1a) sampling error arising 
from the smaller numbers of recorded death in early and late adult life, and biases 
arising from historically changing diagnostic accuracy and estimates of five-year 
survival rates. This comparison yielded a GOF(h,t) of 0.043 that serves here as a best 
available approximation of the minimum GOF(h,t) that may be expected between any 
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model and the age-specific incidence data. This is akin to an average standard 
deviation of +/- 5 % for the estimate for each of eighteen five-year age of death 
intervals. Not included in this estimate are any age-specific ascertainment biases such 
as may be expected if the accuracy of cause of death diagnoses declines in extreme 
old age relative to younger ages. Were an underestimate of 30% postulated for the 
four oldest age of death intervals then the GOF(h,t) of an accurate model would be 
about 0.08. Given these boundaries it seems appropriate to reject the null hypothesis 
if GOF(h,t) exceeds 0.16 for any set of model conditions as this accounts to a 
reasonable degree for both uncertainty in the accuracy of the incidence data and the 
errors associated with sampling. 
First, the best fits of CAL(h=1890-99, 15< t <104) were calculated for the twenty-five 
combinations of n = 1-5 and m = 1-5 under the parsimonious conditions of 
homogeneous risk and no synchronous mortal diseases sharing risk factors with 
colorectal cancer. Values of (∏Ri)1/nand (∏RA)1/m were permitted to range from 10-9 
to 100 and the range of µ was set at 0.1 to 0.3. The complete matrix of results is 
provided in Supporting Information as Table S3. The value of 0.052 was the 
minimum GOF(h,t) observed for n = 4, m =2. For n = 2, an appropriate biological 
value if only the loss of both copies of the APC gene were necessary and sufficient for 
initiation in most colorectal cancers, and m = 1, a default assumption absent any 
evidence about mutations required for promotion, the GOF(h,t) was 0.085. It should 
be noted that discordance was greatest at t >75 yr where underestimation of colorectal 
cancer as a cause of death by as much as 30% has been suspected in extreme old age 
[13-16].  
Second, we observed the best fits of CAL(h,t) under the additional assumption of 
inhomogeneous risk, i.e., the parameter “F” representing a hypothetical fraction of the 
population at risk was allowed to range from 0 to 1. The values of GOF(h, t) ranged 
from 0.035 (n = 3, m = 4) to 0.064 ( n = 3, m = 5). The value of 0.043 was the 
minimum GOF(h,t) observed for n = 2, m = 1. Further discussion of “F’ and the 
complete matrix of these results is provided in Supporting Information as Table S4.  
Thirdly, we considered the possibility of both population inhomogeneity and a 
competing synchronous mortal disease having genetic and/or environmental risks 
shared with colorectal cancer, i.e., the parameter “f” representing this possibility was 
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allowed to range from 0 to 1 as discussed in Supporting Information. This assumption 
did not, however, further reduce the values of GOF(h,t).  
Figure 3 depicts the degree of concordance of the two trial conditions: F = 1, f = 1 
(population homogeneity, no synchronous competing risk) and F < 1, f =1 (population 
inhomogeneity, no synchronous competing risk)) with adult lifetime incidence data 
for lower G.I. tract cancer in European American males born 1890-99 INC(h,t). The 
model presented herein incorporating the observation of limitation of mutation to the 
fetal/juvenile period but without the assumption of risk stratification fits the data well 
except at extreme old age when it predicts incidence rates as much as 30% higher 
than recorded. Assuming accuracy of the data in old age, when the model accounts 
both for the fact of fetal/juvenile mutation limitation [17] and the possibility of risk 
stratification in the population (F <1) fits are sensibly improved.  
 
DISCUSSION  
We find that the observed lifetime adult age-specific incidence of colorectal cancer in 
European-American males born 1890-99 or 1900-09 are wholly consistent with 
initiation limited to the stem cells of the fetal/juvenile period. We further find that 
when APC initiation mutation rates derived from observations in FAPC patients are 
employed the model is consistent with observation only if n = 2 initiation mutations 
are employed.  
Fetal/juvenile mutation. 
Early models posited that a constant number of adult cells were at continuous risk of 
acquisition of a required set of oncomutations that resulted in lethal tumors [18-20]. 
Platt’s questions about selective growth advantage of early oncomutants [21] 
stimulated the creation of the two-stage model of Armitage and Doll in which 
initiation was restricted to a constant number of adult cells [3]. An alternate theory, 
fetal/juvenile or, more narrowly, gestational initiation was based on Luria’s 
demonstration that in a bacterial culture growing from a small number of cells early 
mutations give rise to large mutant colonies and late mutations to small ones [22]. 
This concept was clearly applicable to the stem cells of a growing organ. By maturity 
a stem cell initiated early in development would create a large preneoplastic colony, 
an initiation in the last juvenile doubling would create a single initiated stem cell. 
Early cancers would arise from early developmental initiation, cancers of extreme old 
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age would arise from the last juvenile initiation events [4, 5, 6, 23]. In the algebraic 
model provided here each successive doubling of stem cells of the fetal/juvenile 
period provides initiated colonies. Deaths from colonies initiated in any specific 
doubling interval are distributed over subsequent periods of life (Figure 2). 
Biological data supporting limitation of mutations to the fetal/juvenile period were 
scant but suggestive. New colonic adenomatous polyps are more rarely detected after 
age sixty [24] whereas if tumor initiation continued throughout life, a continuing 
increase in polyps would be expected [7]. The first direct evidence of a juvenile 
limitation of a human parenchymal tissue mutation was offered by Brash and Pontén 
who reported that increases in mutant TP53 colonies in human skin were restricted to 
the juvenile years and subsequent solar exposure in adults increased mutant colony 
size but not number [25, 26]. More recently, the distribution of five nuclear and 
seventeen mitochondrial point mutations in adult human lung epithelium was found to 
match a simple Luria-Delbruck expansion of mutant stem cells for ten stem cell 
doublings prior to maturity without further increase in adult life [9, 25].  
Mutator/hypermutable metakaryotic stem cells of organogenesis and 
carcinogenesis. 
The observed high fetal/juvenile mutation rates have been associated with amitotic, 
non-eukaryotic cells that arise in the 4th-5th week of gestation that appear to serve as 
the stem cells of human organogenesis and carcinogenesis [7 – 10]. These large 
“metakaryotic” cells with bell shaped nuclei found in human fetal/juvenile organs, 
preneoplastic lesions and neoplasias increase by symmetric amitotic fission and have 
been observed to produce all parenchymal, subsequently mitotic, cell forms by 
asymmetrical mitotic fissions in tissues derived from all three primordial germ layers 
[10]. Metakaryotes display a bizarre mode of DNA segregation that occurs prior to, or 
concomitant with, DNA replication in sister cells [10] that appears to involve DNA 
copying by DNA polymerase β insofar as about half of cancer-initiating APC point 
mutations sampled are attributable to errors of DNA polymerase β copying 
undamaged DNA in vitro [11]. 
Environmental cancer risks during the fetal/juvenile period. 
Agreement between the origins of adult somatic mutations in mutator/hypermutable 
fetal/juvenile human stem cells and age-specific cancer rates offers an explanation of 
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epidemiological associations between fetal and early childhood exposure to known 
mutagenic stimuli, particularly sunlight [26, 27].  
Generational changes of age and organ-specific cancer rates in immigrant populations 
towards those of the new country of residence may also be thought of in terms of 
fetal/juvenile initiation mutations. Adult immigrants would have experienced tumor 
initiation in the country of origin while early in utero immigrants would experience 
the tumor initiations specifying risk after age 20 in the new country. In both older and 
younger immigrants the environment of the new country would define promotional 
stresses that might act by inducing promotional oncomutations and/or by selecting 
through growth stimulation conditionally initiated stem cells acquired in the 
fetal/juvenile period [28].  
Similarly, the marked decrease in death rates from lower G.I. tract (Fig. 1d.) and other 
incurable cancers in children and young adults may be attributable to a decline in 
fetal/juvenile initiation rates that began circa 1940 and continued through 2006 
[http://mortalityanalysis.mit.edu].  
Save for sunlight exposure of juveniles, however, there is no direct evidence that 
environmental mutagens cause mutations in humans [29]. “Spontaneous” mutation 
caused by simple DNA polymerase mis-incorporation errors or errors following DNA 
damage by endogenous processes may account for all fetal/juvenile mutations save 
for juvenile mutation by sunlight[11, 30]. Environmental mutagens may have been or 
still may be indirectly responsible for some of these oncomutations  
The assumption of population homogeneity. 
If it is posited that the population is in some way inhomogeneous with regard to risk, 
F < 1, the fit to the recorded INC(h,t) is sensibly improved (Figure 3). One form of 
risk stratification is represented by the ~tenfold range in colonic adenomatous polyp 
numbers observed among individuals of FAPC families [2] that indicate a range of 
fetal/juvenile APC mutation rates. A similar variation of numbers of mutant crypts 
displaying loss of the second allele of sialylmucin O-acetyl transferase (OAT) has 
been observed in adult colon [31]. The discrepancies between the two-stage model 
adjusted for fetal/juvenile initiation and the colorectal cancer incidence data may thus 
lie principally in the assumption of a homogeneous oncomutation rate that assumes a 
Poisson distribution of initiating events among persons in each organogenic doubling 
period. The wide and approximately rectangular distribution of estimated lung 
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fetal/juvenile mutation rates suggests that the fraction of persons without any 
initiation events by maturity is significantly greater than predicted by the assumption 
of mutation rate homogeneity [9]. This error is compensated in part by positing a 
value of F <1 (Figure 3).  
The assumption of synchronous competing forms of death. 
Assuming a competing synchronous form of death with shared risk(s) with colorectal 
cancer does not further increase goodness of fit under best-fit conditions (Figure 3, 
Supporting Information Table S3) in accord with epidemiological studies of familial 
colorectal cancer [17]. This possibility must however be considered for cancers such 
as breast and ovarian cancers in which synchronous age-specific death rates display 
shared familial risk. 
Number and rates of required initiating mutations. 
Patients heterozygous for the APC gene are reported to have some “hundreds to 
thousands” of adenomatous polyps in adulthood presumably resulting from a single 
mutation inactivating the single active inherited APC allele [1, 2]. The last stem cell 
doubling would be expected to account for half of the total polyp number, the 
penultimate doubling for one quarter and so forth. With an estimated geometric mean 
of ~1000 polyps among 107 total colonic crypts we may therefore estimate that the 
rate of loss/inactivation of the normal parental APC allele occurs at ~(1000/2)/107 = 5 
x 10-5 events per stem cell doubling. The similarly estimated geometrical mean rate of 
loss of the second allele of sialylmucin O-acetyl transferase (OAT) is also ~5 x 10-5 
[31].  
The term ((∏Ri)1/n) represents the geometrical mean of “n” initiating mutations. 
Estimates of this parameter derived from best fits of the model given the assumption 
of population stratification for n = 2 and m = 1-5 were 3.5, 2.3, 2.8, 2.8 and 4.3 x 10-5 
respectively (Figure 3) [12] agreeing well with estimates from clinical enumeration of 
mutant polyps or crypts [1, 2]. For n = 1, m =1, F <1, the rate estimate of ((∏Ri)1/n) is 
about 5.3 x 10-8, for n = 3, m = 1, F < 1 about 2.8 x 10-4. Values of the geometrical 
mean of initiation mutations assuming values of n other than 2 are thus clearly 
discordant with APC and OAT colonic mutation rate estimates. These facts, derived 
from clinical genetic observations in both inherited and sporadic forms of colorectal 
cancers are wholly consistent with the conclusion that n = 2 and inconsistent with 
values of n ≠ 2. 
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Estimation of preneoplastic growth rate, µ . 
Using the best fit stipulated values for n = 2, F < 1 and any value of m = 1-5, the 
preneoplastic growth rate “µ” was estimated to be ~0.18. This is close to the juvenile 
growth rate of mass in males, 0.158, and females, 0.167 [12-14].  
Numbers and rates of required promotion mutations.  
It does not yet seem possible to estimate “m” or the related geometrical mean of 
promotion mutation rates, ((∏RA)1/m). Reasons for this limitation are discussed in 
Supporting Information.  
 
SUMMARY 
Quantitative analysis of age-specific colorectal cancer incidence rates indicate that 
they are wholly consistent with the hypothesis that initiation mutations occur only in 
the fetal/juvenile period. When matched to fetal/juvenile APC mutation rates derived 
from observation of polyp number in FAPC patients the number of initiation 
mutations is consistent with two and only two rare initiation events. Population risk 
stratification for initiation mutation rates is indicated by a wide distribution of mutant 
numbers in adult colons and accounting for said stratification improves the 
concordance with age-specific colorectal cancer rates. 
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FIGURE LEGENDS 
Figure 1. Lower gastrointestinal cancer in European American males, calendar 
years of death, 1890 to 2006 . 1a. Transformations linking raw mortality rates, 
OBS(h,t), with estimates of incidence rates, INC(h,t). Shown are the raw mortality 
rate function, OBS(h,t), for h = 1890-99 corrected for coincident forms of death 
which becomes the function OBS*(h,t) which, in turn, corrected for historically 
increasing survival rate, becomes the incidence rate function, INC(h,t). Also shown is 
INC(h=1900-09, t). 1b. OBS*(h, t), coincidence corrected death rates for birth cohort 
intervals, h = 1800-09, … , 2000-06, vs. age intervals of death, “t” = 0.5, 1, 2, 3, 4, 5-
9, …, 100-104. 1c. OBS*(h,y), coincidence corrected death rates for birth decade 
intervals, h vs. calendar year of death intervals , “y”=1900-1904, …, 2000-2004, 
2005-2006. 1d. OBS*(t,y), coincidence corrected death rates for intervals of age at 
death “t” vs. calendar year of death intervals, “y”. 
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Figure 2. V(a -> g). Expected number of lethal events/person at lifetime stem cell 
division “g”, arising from initiation at fetal/juvenile division “a”. Here it is 
assumed that g = a = 0 at the embryonic turning point ~4-5 weeks of gestation, g = a 
= 20 at birth (t = 0) and g = a = amax= 23.25 at maturity (t =17.5). In adult males “g” 
increases with age according to the relationship g = µ(t - 19) + 23.25. Note that 
earliest initiations presage fetal, juvenile and young adult deaths. Late initiations 
account for deaths in extreme old age. Note also that in this example the SUM of all 
values V(a->g) at stem cell division age “g”, increases sub-exponentially from g = 23 
to a maximum at g = 37 and then declines rapidly. In this example g = 37 represents ~ 
105 yrs of age. [Stipulated parameter values for this example: n = 2, m = 1, µ= 0.16, 
(RiRj)1/2 = 2.2 x 10-5 and RA = 4.4 x 10-5 with homogeneous risk (F = 1) and absence 
of competing synchronous forms of death with risk factors shared by colorectal 
cancer (f=1)]. 
 
Figure 3. Comparisons of observation INC(h,t) to CAL(h,t) for the two-stage 
cancer model with varying assumptions. n = 2, m = 1 is stipulated for all 
examples. (a.) CAL(h,t), homogeneous risk, no synchronous competing form of 
death (parsimonious model, F = 1, f = 1). GOF(h,t) = 0.085. (b.) CAL(h,t), 
heterogeneous risk (F = 0.43, no synchronous competing form of death (f = 1)) . 
GOF(h,t) = 0.043. For CAL(h,t), heterogeneous risk (F < 1), synchronous competing 
forms of death (f < 1). GOF(h,t) = 0.041. See Supporting Information (Table S4) for 
definitions and ranges of “F” and “f” employed. 
 
